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Combined report on regular dialysis and transplantation in Europe,
XIII, 1982. Part I. A. J. Wing, M. Broyer, F. P. Brunner, H. Brynger, R.
A. Donckerwolcke, C. Jacobs, P. Kramer, and N. H. Se/wood with S.
Challah. The statistical report on treatment of endstage renal failure in
32 European countries in 1982 will be based on data returned on
individual patient questionnaires which have been sent to approximate-
ly 1,700 centers. The total number of patients registered is expected to
exceed 145,000 of whom 90,000 will be alive on treatment on December
31, 1981. For the XXth meeting of the Association, the Registry has
researched its patient files for the earliest, oldest, and youngest patients
on record. In keeping with the special topic for the meeting, profiles will
be presented for patients with hypertension and renal stone disease
given as causes of endstage renal failure. The rates of movement of
patients between modes of therapy in different countries in selected
years will be presented to compare the patterns of integration of
therapies. Therapy failure ('drop-out') rates will be compared to
determine their effects on the changing proportions of patients alive on
different treatments. Some patients have recovered function of their
own kidneys after prolonged renal replacement therapy. Results of a
mini-questionnaire regarding these patients will be given. The observed
incidence of malignant diseases will be compared with the expected
incidence.
Combined report on regular dialysis and transplantation in Europe,
XIII, 1982. Part II. F. P. Brunner, M. Broyer, H. Brynger, R. A.
Donckerwolcke, C. Jacobs, P. Kramer, N. H. Se/wood, and A. J. Wing
with N. Gretz. The number of European patients who owe their lives to
functioning grafts is expected to exceed 15,000 by December 31, 1982.
Approximately 5,000 transplant operations will have been carried out
during 1982. Various aspects of patient and graft survival will be
presented and discussed. Causes of graft failure will be analyzed
according to diagnosis of primary renal disease. The frequency and
distribution of primary renal diseases in patients starting renal replace-
ment therapy during the last 10 years will be analyzed. The number of
new patients accepted for treatment in countries reporting to the
Registry reached 5,000 for the first time in 1972 and was three times this
number in 1982. Center practice for treating acute renal failure has been
recorded on the center questionnaire. Diagnostic facilities, attitudes
regarding blood transfusion, use of machine perfusion of cadaveric
kidneys, and type of transplant co-ordinator in transplanting centers
will be summarized.
Combined report on regular dialysis and transplantation in Europe,
XIII, 1982. Part III. R. A. Donckerwo/cke, M. Broyer, F. P. Brunner,
H.Brynger, C. Jacobs, P. Kramer, N. H. Se/wood, and A. J. Wing with
S. Cha/lah. On December 31, 1982 there will be more than 3,000
patients aged less than 15 at the time of first treatment still alive, of
whom 40% will have grown into young adults (aged more than 15). The
1982 Report will give attention to renal transplantation in children
focusing on facilities, waiting time on dialysis before transplantation,
causes of death and transplant failure, and the influence of steroid
treatment on growth. Several aspects influencing survival following
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transplantation will be included. Data on aseptic necrosis of bone have
been collected on a special pediatric questionnaire. The contribution of
CAPD to the treatment of children and results achieved will be
described.
'Y' connector system for prevention of peritonitis (PE) in CAPD: A
controlled study. R. Maiorca, A. Canta/uppi, G. C. Cancarini, A.
Scalamogna, A. Strada, G. Graziani, S. Brasa, and C. Pontice/li. Osp.
Maggiore Mi/ano and Speda/i Civili Brescia, Italy. To compare two
different connector systems, a prospective controlled trial was per-
formed in 54 CAPD patients: 27 patients (17 male, 10 female, aged 56
16 years, mean CAPD time 10 5 months) were randomly assigned to
use the Travenol spike connector (group A) and 27 patients (13 male. 14
female, aged 56 13 years, mean CAPD time 10 5 months) to use a
modification of the 'Y' connector previously described (group B). The
connector was filled with natrium hypochlorite (5,000 ppm/liter of free
available chlorine) that allowed sterilization even after the potentially
contaminating acts of connection-disconnection. Before fresh solution
was infused into peritoneum, the disinfectant agent and the killed
bacteria were washed off from the catheter through the outflow branch.
In group A, 27 PE occurred in 14 patients (52%) during a cumulative
period of 279 months, that is, one PE every 10.3 patient-months. In
group B, 8 PE occurred in 7 patients (26%) during a cumulative period
of 269 months, that is, one PE every 33.6 patient-months. Comparing
the PE probability curves of the two groups, a significant difference (P
<0.01) was found. In conclusion, this study demonstrates that the 'Y'
system significantly reduces the incidence of FE in CAPD patients
when compared to the classic method.
Improved lymphocyte transformation in vitro of patients on CAPD
dialysis. E. Lan ghoff and J. Ladefoged. Medical Department P. Divi-
sion of Nephro/ogy, Rigshospita/et, Copenhagen, Denmark. Previous
reports have demonstrated a decreased response of lymphocytes to
mitogens in chronic uremia. Recently the beneficial effect of CAPD
dialysis has been stated. The present investigation, therefore, examines
whether patients on CAPD dialysis have an improved lymphocyte
response to mitogens and an improved resistance to the suppressive
effect of methylprednisolone (MP) on this response in vitro. Peripheral
blood lymphocytes (PBL) were isolated on lymphoprep® and T cells by
the E-rosetting technique from II patients on CAPD, and 11 patients on
HD, and II control subjects. Both PBL and T cells were stimulated
with mitogens (PHA, Con A) and cultured for 72 hr followed by 20 hr
incubation with '4C thymidine before harvesting and counting the
isotope uptake. The in vitro resistance to steroids was tested by the
addition of 0, 0.05, 0.25, 0.5, 1.0 g MP/ml of culture. Both patient
groups were matched according to the duration on dialysis, and age-
and sex-matched to control subjects. The proliferative responses of the
PBL and T cells to PHA and Con A were identical in CAPD and control
cultures and significantly higher than in HD cultures (P < 0.05). Both
PBL and T cells from CAPD and control cultures were significantly
more resistant to the suppressive effects of MP than HD cultures (P <
0.05). The number of peripheral lymphocytes were similar in all three.
In conclusion, the improved in vitro cell proliferation and resistance to
steroids during CAPD treatment may reflect an improved form of
dialysis, which may be important for the patients' general immune
defense.
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Severe abdominal complications in patients undergoing continuous
ambulatory peritoneal dialysis. J. Rottembourg, G. M. Gahi, J. L.
Poignet, E. Mertani, P. Strippoli, J. P. Langlois, and M. Legrain.
Department of Nephrology, Hôpital Ia Pitié, Paris, France. In a long-
term experience (198 patient-years) dealing with 143 patients (93 males,
50 females) with a mean age of 61.2 16.3 years treated by Continuous
ambulatory peritoneal dialysis (CAPD) during an average period of 16.6
patient-months (range, I to 48 months), the following abdominal
complications were observed: 244 acute peritonitis episodes (I per 9.8
patient-months) including 8 perforated peritonitis, 8 encapsulated sub-
acute peritonitis, 2 necrotizing enteritis, and 6 severe gastro-intestinal
bleeding. Such complications led directly to death in 10 patients (36% of
all deaths) and required transfer to hemodialysis (HD) in 21 patients
(51% of all transfers). Spontaneous perforation of colonic diverticula
was observed in six patients, three times in a closed cavity. One patient
died after surgery, five patients were transferred to hemodialysis, in
two cases after colectomy. Subacute encapsulated peritonitis occurred
in eight patients with a mean CAPD treatment of 19 months and a mean
rate of acute peritonitis of 4.1. per patient (range, 0 to 11). Symptoms
were deterioration of ultrafiltration, recurrent subocclusion, and malnu-
trition. Surgical cure after laparotomy performed in six patients was
impossible. Four deaths were observed despite transfer to HD in seven
patients. Necrotizing enteritis of unknown origin leading to death was
observed in two patients. Severe abdominal complications remain the
major cause of drop out of patients on CAPD and represent the major
limiting factor to consider CAPD as an alternative to HD for a long-term
treatment of patients with endstage renal diseases.
Multicenter study of physical activity and employment status of contin-
uous ambulatory peritoneal dialysis (CAPD) patients in the United States.
J. Fragola, S. Grube, L. Von Bloch, and E. Bourke. Allegheny General
Hospital, Pittsburgh, Pennsylvania. Rehabilitation (R) data from the
European registry may reflect more restrictive selection criteria than in
the United States. The only comparable U.S. survey concentrated on
hemodialysis (HD). We report the findings of an anonymous question-
naire in which 125 centers comprising 1215 CAPD patients (20% of the
CAPD population in the United States), distributed among urban and
rural areas, participated. The focus was on readily available information
deemed essential to any final analysis of R. Seventeen aspects amena-
ble to statistical analysis were addressed including demography, educa-
tional level, work/employment status, semiqualitative Karnofsky scale
analysis of physical performance pre- and post-institution of CAPD,
duration of CAPD, and prior therapeutic modalities, the presence of
diabetes, visual impairment or peritonitis, and patient perception of
CAPD. There were nearly as many females as males (45:55), 18% were
diabetic patients (D) whose mean age, 46.3 years old, was less than non-
diabetic patients (ND) 52.3 years, (range, 10 to 92). Whereas ND who
were capable of greater activity than just taking care of themselves
(66%) were similar to HD patients in the United States, the findings in D
(48%) were better for CAPD than for HD. Although more D (28.7%)
than ND (12.1%) were incapable of self-care among CAPD patients,
these percentages are significantly lower than for the corresponding HD
patients in each category. Of those less than 65 years old who were
working outside the home prior to starting CAPD, 41% continued to
work (10 hr or more/week), the figure being higher among skilled than
nonskilled persons. We conclude that some parameters of R appear
better for CAPD than for HD patients.
Short hemodialysis—long-term results. J. P. Wauters and S. Pansiot.
Division of Nephrology, University Hospital, Lausanne, Switzerland.
The safety of long-term of short hemodialysis (SHD) still remains
questioned. Since 1976 we have used a three times 3 hr/week schedule
adapted individually. Fifty-eight patients, aged 25 to 76 years (mean 52)
have been treated for more than 3 years. The dialyzers, exclusively
capillary filters were re-used twice. Pre-dialysis values (mean 5EM)
were:
Cre-
Years N BP mm Hg
atinine
.smoles/liter Ht vol/liter
MNCV
m/sec
0.5 58 148 4/84 2 1015 32 0.24 0.008 50 2
3 58 155 3/86 2 1082 24 0.25 0.008 47 I
5 34 149 4/87 2 1116 32 0.29 0.014 45 I
6 Il 138 5/83 3 1177 67 0.30 0.027 48 2
In a subgroup of 14 patients treated first with "conventional" (three
times 5 hr/week) then with SHD, the biological parameters which
changed significantly after 5 to 6 years of SHD were Ht (from 0.25 to
0.32 vol/liter) and alkaline phosphatase (from 38 to 53 lU). SHD did not
increase dialysis side-effects, was preferred by all the patients and
allowed a better socio-professional rehabilitation. The number of oral
medications did not increase throughout the years. During the follow-up
period, seven patients out of 58 died (two of cardio-vascular events),
nine were transferred to other treatment modalities. In conclusion, for
58 hemodialyzed patients treated three times 3 hr/week for more than 3
years, it appears that short hemodialysis (1) may be safely applied for at
least 6 years, (2) allows biological values within the expected limits to
be maintained, (3) has a mortality and morbidity comparable to those of
longer treatment schedules, and (4) is preferred by the patients.
Clinical evaluation of a new thrombin inhibitor suitable for hemodialy-
sis. K. Ota, S. Nakagawa, S. Koshikawa, K. Maeda, N. Matsui, Y.
Hirasawa, and T. Sasaoka. Tokyo Women's Medical College, Tokyo
Medical Dental University, and Showa University, Tokyo; Fujigaoka
Hospital, Yokahama; Nagoya University Branch Hospital, Nagoya:
Shinrakuen Hospital, Niigatashi; Tsuchiura Kyodo Hospital; Yokosuka
Kyosai Hospital, Japan. Heparin has been used as the sole anticoagu-
lant for hemodialysis. It is well known, however, that the drug has
inherent effects on lipid and bone metabolism. A new thrombin inhibitor
(MD-805), which has arginine in its molecular structure, has been
evaluated for clinical application. The mechanism of anticoagulation is
that the drug has higher affinity to thrombin than fibrinogen, and
accordingly formation of fibrin is inhibited even in the absence of
antithrombin Ill. The anticoagulant used for hemodialysis was switched
from heparin to MD-805 and maintained for 12 weeks in SI patients.
Data obtained were compared with those of heparin dialysis. The
results revealed that the drug in a dose of 25 mg/hr, having similar
anticoagulability to heparin during the dialysis, caused no decrease of
triglyceride or elevation of free fatty acid. While pre-dialysis levels of
antithrombin III rose significantly after 4 weeks of treatment, no
significant change was observed in serum cholesterol, triglyceride, free
fatty acid, HDL-cholesterol. a,/3, and y lipoprotein and fibrinogen. No
serious side effect was observed in any of those patients. From these
findings, it is concluded that MD-805 is a potent anticoagulant suitable
for hemodialysis instead of heparin which has inherent side effects on
lipid and bone metabolism.
Transfused and pharmacological iron: overload related to HLA anti-
gens. M. Taccone-Gallucci, M. El/i, G. D. Di Nucci, C. Meloni, M.
Va/en, D. Adorno, G. Mariani, F. Mandelli, and C. U. Casciani. V
Patologia Chirurgica e Ematologia Universita di Roma, Italy. It has
recently been suggested that dialyzed patients (DP) bearing hemochro-
matosis antigens (HA) are at an increased risk of iron overload. Serum
ferritin (SF) levels and the frequency of HLA A3, B7, and Bl4 were
assessed in 48 DP for 6 to 139 months. None of them had evidence of
liver disease or infection or differences concerning the iron dietary
intake. None of the DP had received oral or parenteral iron or blood
transfusions for the last 3 months prior to our study. Mean SF levels
were significantly higher in 15 DP with HA (HA+) (439.21 178.47 ng/
ml, 5 + SEM) than in 33 DP without HA (HA—) (166.22 33.79). The
difference between SF remained statistically significant in HA + DP
who had been transfused during the last 15 months (760.37 296.19) in
comparison to those who had not (70.31 24.66). Previous transfusiQns
did not influence SF in HA— DP (transfused 190.16 52.52; not
transfused 152.54 44.48). In addition SF in transfused DP was
significantly higher in HA+ DP (760.37 296.19) compared with HA—
DP(l90.16 52.52). The difference between SF related to HA was not
statistically significant in nontransfused DP. To evaluate the effect of
parenteral administration of iron on SF 200 mg x S of iron saccarate
was given intravenously after dialysis to 13 HA— and 7 HA+ DP.
Parenteral iron administration induces a statistically significant increase
of SF, as evaluated both at IS and 30 days after the administration,
regardless of the HA status. Our results suggest that blood transfusion
may represent a relevant risk factor of iron overload in DP with HA.
Parenterally administered iron may cause an iron overload regardless of
the antigenic status of the DP.
Dopaminergic control of sympathetic activity and blood pressure (BP)
in hemodialysis (HD) patients. A. Sturani, C. Chiarini, E. Degli Esposti,
A. De March, G. Fuschini, A. Santoro, A. Zuccald, C. F/a,nigni, and
P. Zucchelli. Division of Nephro/ogy and Dialysis, Malpighi Hospital,
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Bologna, Italy. Bromocriptine was used to test the hypothesis that the
abnormality of the dopaminergic system described in HD patients may
cause enhanced sympathetic activity and high BP. Hormonal and BP
responses to tilt and cold pressor tests were examined in six hyperten-
sive HD patients after a week of treatment with bromocriptine (2.5 mgI
day). The data were compared to those obtained during a placebo
period. All HD patients were hyperprolactinemic. Bromocriptine signif-
icantly reduced supine mean BP (119 4.7 vs. 106 4.9 mm Hg, P <
0.01) and plasma noradrenaline (278 58 vs. 173 45 ng/liter, P <
0.05). However, the associated reduction in heart rate was not signifi-
cant. Moreover, although the increments in plasma noradrenaline
during tilt test were reduced by bromocriptine. there was a significant
improvement in the response of mean BP (—4.8 + 1.1 vs. 2.8 1.7 mm
Hg, P < 0.05). The same results were observed during the cold pressor
test. These results suggest that dopaminergic control of sympathetic
activity may be impaired in HD patients and may be a cause of high BP.
Moreover, the reduction observed in sympathetic activity may up-
regulate the adrenergic receptors and consequently may enhance BP
responses to endogenous noradrenaline during the tilt and cold pressor
tests.
Effect of vaccination schedule and dialysis on HbS vaccination response
in uremic patients. J. Bommer, E. Ritz, K. Andrassy, F. Deinhardt, G.
Darai, and W. Jug. Departments of Internal Medicine and Immunolo-
gy, University of Heidelberg and Pettenkofer-Institut, Munich, Federal
Republic of Germany. Immunoregulation is abnormal in uremic pa-
tients; an increased propensity for hepatitis HbS is paralleled by
diminished response to HbS vaccination. We examined whether modifi-
cation of vaccination schedule improves HbS antibody(ab) response,
whether concomitant administration of hyperimmune globulin and
vaccination (passive/active) is effective and whether dialysis in itself
interferes with vaccination success. MSD HbS vaccine was given to 44
staff (22 male; 22 female), 84 dialysis patients (56 males, 28 females),
and 12 non-dialyzed patients with preterminal uremia. Group I vaccine
month 0, I, 6; group 2 vaccine month 0, I, 2, 4,6; group 3 vaccination
month 0, I, 2, 4, 6 with 3 ml hyperimmune globulin month 0, 2. After 7
months seroconv.ersion in staff (10 g) occurred in 93%. Median
"titers" were 106. Patient group 1 (20 g) had seroconversion in 48%.
Median "titer" was 24.5. Patient group 2 had seroconversion in 59%
(median "titer" 108). Patient group 3 had seroconversion in 58%
(median titer 119). Preterminal non-dialyzed uremic patients vaccinated
like group I had seroconversion in 50% (median "titer" 28). We
conclude that despite higher MSD dose seroconversion occurs less
frequently in dialysis patients than in age-matched staff. This confirms
previous reports. However, it could be demonstrated that more fre-
quent vaccination increases median titers and the rate of seroconver-
sion to a lesser extent. Simultaneous vaccination and administration of
hyperimmune globulin (important after acute exposure) did not inter-
fere with vaccination success. Similar results occurred in the dialyzed
and non-dialyzed term. Uremic patients suggest that HbS vaccinations
should be considered in incipient renal failure.
Open heart surgery in patients with endstage renal disease (ESRD). J.
Rottembourg, T. Mussat, I. Gandjbakhch, A. Barthelemy, D. Tale-
dano, G. M. Cahi, and C. Cabrol. Departments of Nephrology and
Cardio Vascular Surgery, Hôpital La Pitié, Paris, France. Cardiovas-
cular diseases have long been recognized as the major complication of
ESRD and dialysis. Some of them require correction by open heart
surgery. Seventeen patients (14 males, 3 females) aged 27 to 58 years
received ten aortic, two mitral valve replacements, and five coronary
artery by-pass grafts. Eleven patients were treated by hemodialysis
(HD) from I to 84 months and two by CAPD; four patients had severe
renal failure (creatinine clearance less than 10 mI/mm). Special attention
was paid to these patients including preoperative dialysis, cardiopul-
monary (CP) by-pass with complete hemodilution, composition of the
extracoporeal circuit volumes, arterial and venous accesses, and myo-
cardial protection. Weight gain was moderate during CP by-pass (1.1
0.4 kg), mean postoperative bleeding was 1200 ml (range, 360 to 2400
ml). HD sessions were performed without heparin 36 to 48 hr after
surgery without bleeding problems and CAPD was reintroduced post-
operatively. Prosthetic valves were preferred to porcine heterografts
because of hyperlipidemia, secondary hyperparathyroidism, and sub-
acute bacterial endocarditis (SBE) following fistula infection. Autolo-
gous saphenous vein grafts were utilized for coronary artery by-pass.
There were no intraoperative deaths. Three early postoperative deaths
occurred: two with SBE and one with extended myocardial infarction.
The follow-up of 14 patients (82%) was available from I to 84 months.
Three patients expired, 6, 9, and 5.25 months after surgery from
hypoglycemia, SBE, and stroke, respectively. Eleven patients are alive
with improved clinical status. Carefully planned open heart surgery can
be successfully carried out in these patients without undue operative
risk.
Renal allograft survival in patients transfused perioperatively only. W.
Fassbinder, U. Frei, E. Scheuermann, P. Bechstein, R. Raah, G.
Dathe, D. Jonas, and W. Schoeppe. Departments of Nephrology and
Urology, University Hospital, Frankfurt, Federal Republic of Germa-
ny. The beneficial effect of preoperative blood transfusions (BT) on
kidney graft survival is well documented, however, optimal timing of
BT is subject to controversy. We investigated in a prospective study the
role of perioperative BT. All patients (N = 105) receiving their first
cadaveric graft since 1979 were transfused perioperatively (that is, 0 to
6 hr before transplantation) with two units of non-washed, unfiltered
packed red cells. Prophylactic antirejection therapy consisted of azathi-
oprine and prednisone only. Patients were divided into two groups:
Group A was transfused perioperatively only and had no prior BT.
Group B was transfused pre- and perioperatively. Actuarial patient and
grafts survival (in percent) is given in the table:
Group
Sur-
vival
Time post
-transplant (months)
—-—
3 12 18 24 36
A Patient 100 100 100 100 100
N = 48 Graft 80.2 77.6 77.6 77.6 77.6
B Patient 94.4 92.3 92.3 87.4 87.4
N = 57 Graft 89.0 84.0 76.0 71.3 71.3
In regard to mean age (39.3 vs. 35.7 years) and average HLA-identities
between donor and recipient, both groups did not differ significantly.
Graft survival has substantially increased since the introduction of
perioperative BT. The data demonstrate well acceptable graft survival
rates in patients transfused perioperatively only. In these patients unde-
sired sensitization with cytotoxic antibodies is avoided, thus increasing
their chance to get a compatible graft after a short waiting time.
A new mechanism of humoral immunodepression in chronic renal
failure and its importance to dialysis and transplantation. P. K. Don nd-
ly, B. K. Shenton, A. Alomran, G. Proud, D. M. A. Francis, andR. M.
R. Taylor. University Department of Surgery, Roal Victoria Infirmary,
Newcastle upon Tvne, United Kingdom. While uremic patients are
known to be anergic, the explanation of this effect is unclear. Increasing
attention is being directed to the presence of noncytotoxic leukocyte
"blocking factors" in the plasma of uremic patients. Our aim was (I) to
investigate the clinical significance of patient plasma suppressive activi-
ty (PSA) on a rapid in vitro assay of normal lymphocyte function (2) to
propose and test an hypothesis to explain the mechanism of this effect.
(1) The plasma of 160 regular dialysis patients exhibited a significantly(P < 0.001) greater PSA than that of 30 normal healthy controls. PSA
decreased significantly (P < 0.05) but transiently after hemodialysis
while blood transfusion caused a rapid and sustained rise in PSA,
maximum at 2 months. Estimation of PSA preoperatively in 146
consecutive renal allograft recipients revealed a group of patients with
low PSA who were significantly more liable to early graft failure from
rejection than those with high PSA. (2) Gel fractionation studies
associated PSA with the plasma protein a2macroglobulin (a2M). PSA.
however, was not correlated with plasma levels of a2M. To explore
qualitative differences in the immunosuppressive properties of a,M, we
studied its role as the "final common pathway" for protease (that is,
plasmin, thrombin, and trypsin) binding and degradation. Assay of the
protease binding capacity of a2M in uremic plasma showed high
suppressive activity due mainly to the persistence of a2M-protease
complex or the abnormal liberation of a suppressive peptide (< 10.000
daltons) into the circulation.
Pretransplant antibodies and renal allograft survival. A. M. MacLead,
R. J. Mason, D. A. Power, N. Edward, K. N. Stewart, G. Shewan, and
G. R. D. Catto. Department of Medicine, University f Aberdeen and
Blood Transfusion Service, Aberdeen, Scotland. The presence of
antibodies in recipient serum prior to transplantation is generally
thought to have a deleterious effect on graft outcome. Cytotoxic
antibodies to autologous lymphocytes have, however, been shown to be
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harmless or in some cases beneficial and to react with normal but not
leukemic (CLL) lymphocytes. We have shown that noncytotoxic Fc-
receptor blocking antibodies detected by the erythrocyte antibody
inhibition assay (EAI) improve transplant survival. We now investigate
the possibility that these are autoantibodies. Pretransplant sera from 24
patients were studied for the presence of both EA inhibiting antibodies
and lymphocytotoxic antibodies at 5°C, 23°C, and 37°C. In only one
patient were EA inhibiting antibodies detected against autologous cells
and in this patient the graft failed in less than a year and no anti-donor of
EAI was present. However, 10 of II grafts with but only 4 of 13 without
anti-donor EAt survived I year (P <0.01). Similarly 13 of 15 grafts with
but only I of 9 without anti-CLL activity and 10 of 12 grafts with and 4
of 12 without anti-normal panel EAI survived 1 year (P <0.001) and (P
< 0.05). respectively. No patient developed autologous lymphocyto-
toxic antibodies against donor T or B lymphocytes although cytotoxic
antibodies were directed against donor, normal panel, and CLL B
lymphocytes in 2, 9 and, 14 patients, respectively. In this study no
autolymphocytotoxic antibodies were detected pretransplant. The EA
inhibiting antibodies directed against donor, normal panel, and CLL
lymphocytes correlated with good graft survival but were not directed
against autologous lymphocytes.
Cytotoxic suppressor cells in renal allograft rejection. D. Taube, K.
Welsh, and P. Hobby (introduced by D. G. Williams). Renal and Tissue
Typing Laboratories, Guy's Hospital, London, United Kingdom. To
study the nature and significance of mononuclear cells infiltrating
human renal allografts in the first month after transplantation, we
stained 48 fine needle allograft aspirates and simultaneous samples of
venous blood from 20 patients with monoclonal antibodies directed
against helper cells (Leu 3a), suppressor/cytotoxic cells (Leu 2a),
macrophages (OKMI), and B cells (B+). Twenty-seven rejection
episodes and 21 nonrejection episodes were studied. Six patients were
studied serially during the first 3 weeks post-transplantation. During
rejection episodes the ratio of Leu 3a°: Leu 2a cells in the allograft
aspirates [0.56 0.32 (I so)I was significantly less (P < 0.00001) than
the ratio of Leu 3a: Leu 2a cells 11.12 0.52(1 so)] in the aspirates
from nonrejecting allografts. There was no significant difference in the
peripheral blood ratio of helper: cytotoxic/suppressor cells during
episodes of rejection and nonrejection. There was also no significant
difference in the numbers of OKMI+ and B+ cells found in the
aspirates or peripheral blood taken during episodes of rejection and
nonrejection. The lower ratios of Leu 3a: Leu 2a cells were found in
allograft aspirates taken during the 3 days before treatment of rejection
episodes. Persistence of these low ratios into the 3 days after treatment
of rejection was associated with either graft loss or further early
rejection, showing that the presence of increased numbers of Leu 2a
may have considerable clinical importance.
Detection of lymphocyte subsets in renal graft biopsy by monoclonal
antibodies. A. Vangelista, A. Nanni-Costa, G. Frascd, and V. Bono-
mini. Institute of Nephrology, St. Orsola University Hospital, Bologna,
Italy. Identification of infiltrating cells in renal graft biopsy may be
helpful in understanding the pathogenetic mechanisms of rejection. This
study reports the results observed in II patients with acute renal graft
rejection. Renal biopsy specimens were tested by the indirect immuno-
fluorescence technique using monoclonal antibodies against T cell
surface antigens (OKT3:T cells; OKT4:T helper-inducer cells; OKT8: T
suppressor-cytotoxic; Leu 7:killer-naturat killer; OKMI:monocytes-
null cells; Leu lO:B cells). Results were expressed as a percentage of
infiltrating cells. OKT8 positive cells were predominant in all biopsy
specimens ranging from 20 to 50% of infiltrating cells. Leu 7 positive
cells were observed in 10 of II patients. The percentage varied from 7 to
30%. 0KM I positive cells were present in all patients ranging from 2 to
30%. B cells were observed in seven instances ranging from 7 to 12%. A
correlation was observed between the percentage of Leu 7 positive cells
and intensity of rejection in nine patients with predominant interstitial
lesions; in the remaining two patients with predominant vascular lesions
a low percentage of Leu 7 positive cells was observed. No correlation
was documented between type and degree of rejection and the remain-
ing T cell subsets.
Renal transplantation: Early detection of obstructed ureter by ultra-
sound. D. L. McWhinnie, J. A. Bradley, J. D. Briggs, D. J. Galloway,
D. N. H. Hamilton, B. J. R. Junor, and P. Morley. Renal Unit,
Department of Surgery and Ultrasound Department, Western Infirma-
ry, Glasgow, Scotland. Ureteric obstruction following renal transplan-
tation may be difficult to diagnose, particularly when the graft is
functioning poorly. Under these circumstances the intravenous uro-
gram may give a poor quality of picture and while the isotope renogram
is a sensitive test, the pattern of abnormality seen with an obstructed
ureter is nonspecific. The purpose of this study was to determine the
value of ultrasound examination in the diagnosis of ureteric obstruction.
Between January 1980 and December 1982, 158 patients underwent
renal transplantation. One hundred and thirty-six of these patients had
serial ultrasound examinations carried out, all patients having a mini-
mum of three examinations with a range from 3 to IS studies per
patient. During this period ten patients (6%) underwent surgery at
which ureteric obstruction was confirmed and successful re-implanta-
tion of the ureter was carried out in all patients. The ultrasound
correctly identified nine of these ten obstructions at an early stage.
There was only one patient in whom ureteric obstruction was falsely
diagnosed by ultrasound. This compares favorably with the use of the
IVU which, in this series, gave two false negative and one false positive
result out of 60 examinations. This study provides evidence that
ultrasound examination is an accurate way of diagnosing ureteric
obstruction following transplantation. It has advantages in comparison
with the IVU in that it is less traumatic to the patient and safer.
Graft function loss in patients with a transplant renal artery stenosis
after captopril treatment. F. J. van der Woude, W. J. ran Son, A. M.
Tegzess, A. J. M. Donker, M. J. H. Slooff, and S. J. Hoorntje. Renal
Transplantation Unit, State Universit Hospital. Groningen, The Neil,-
erlands. We evaluated nine patients with hypertension due to a trans-
plant renal artery stenosis (TRAS). In these patients captopril treatment
always resulted in a dramatic decrease in renal function not attributable
to a blood pressure drop. Two patients who were also treated in
addition with acetazolamide developed anuria. In four patients surgical
reconstruction ultimately led to a satisfying recovery of renal function
and an acceptable blood pressure with minimal antihypertensive medi-
cation. However, in two other patients recovery was not uneventful:
one patient underwent a transplantectomy of an ischemic graft. In the
other patient an attempt to surgical reconstruction failed, hypertension
persisted, and the creatinine clearance remained 18 mI/mm. In one
patient graft function could be partly restored by discontinuation of the
diuretics and captopril and by augmentation of the sodium intake. Only
in two patients with a stenosis in one out of two renal arteries. captopril
resulted in a therapeutic blood pressure drop. In these two patients
captopril induced a chemical amputation of the poststenotic renal
tissue. We conclude that captopril treatment in nine patients with a
TRAS led to a very pronounced deterioration of graft function. This and
the possibility of surgical reconstruction stresses the Importance to
detect a TRAS in renal transplant recipients with hypertension.
Therapy and prognosis of de novo membranous glomerulonephritis
following kidney transplantation. F. Vincenti. B. Berger, C. Biava, W.
Amend, N. Feduska, and 0. Salvatierra (introduction h' F. Brunner).
University of California, San Francisco, California. Eight of 936
patients who underwent kidney transplantation between January 1974
and June 1981 developed de novo membranous glomerulonephritis
(DNMGN). There were five males and three females. All patients had
nephrotic range proteinuria with a mean onset of 18 months (range, 4 to
30) after transplantation. Mean protein excretion was 10.5 g (range. 4.0
to 18.9). The mean creatinine clearance was 79 mI/mm (range. 56 to
110). All patients were HB5Ag negative. The follow-up as of January
1983 averaged 48.8 months (range, 21 to 101). Graft loss occurred in two
patients who had histological findings of rejection in conjunction with
the membranous lesions 17 months after developing DNMGN. Four
patients were not treated with additional prednisone for the DNMGN.
Proteinuria has persisted in three patients and improved in one patient
(from 6.6 to 2.2 g). Only one patient has had deterioration of renal
function (serum creatinine from 1.1 to 3.9 mg%) thought to be related to
superimposed rejection. Follow-up observations are available in two of
three patients (one patient having been just started on the prednisone
pulse) treated with additional prednisone for the DNMGN. Renal
function in both patients has remained stable and proteinuria has
declined to normal in one and to 1.2 g in the other patient. In
conclusion, the prognosis of DNMGN appears to be good unless it is
associated with rejection. Use of additional prednisone for the treat-
ment of DNMGN should be considered with caution since it is not clear
if it is beneficial.
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Prevention of osteonecrosis following renal transplantation by using
vitamin D2(ergocalciferol). D. Scholz, M. Mebel, I. Topelmann, I.
Grossmann, and J. Schoize. Departments of Urology and Radiology,
Humboldt-University, Berlin, German Democratic Republic. Osteone-
crosis (ON) is a frequently disabling complication of renal transplanta-
tion (RT). The present study was undertaken to find out whether
vitamin D2 can be used in RT-patients for prevention of ON. We
examined the incidence of ON in a group of 244 CD-RT patients and
analyzed the risk factors that may contribute to its development.
Osteonecrosis developed in 31 of 244 patients (12.7%), who received
CD-renal transplants from 1968 to 1978 and were observed for more
than 4 years (maximum of 14 years). For the analysis of factors
contributing to the development of ON, each patient with ON was
matched with the following RT patient There were no differences
between the 14 factors in the groups with the exception of the following
data:
Osteonecrosis
Patients
(N=31)
Control Patients
(N=3l) P
>3 pulse doses of 12 of 31 I of 31 <0.01
prednisolone
Serum creatinine 20 of 31 9 of 31 < 0.01
level > 1.5 mg/dl
Steroid diabetes 16 of 31 7 of 31 < 0.02
mellitus
One hundred sixty-nine patients were treated with vitamin D2 (15,000 to
20,000 U daily by mouth) without side effects (duration of vitamin D,
supplements, 4.5 2.1 years). The incidence of osteonecrosis with the
prophylactic vitamin D2 was II or 6.5% (N = 169 patients); without
vitamin D2, the incidence was 20 or 26.7% (N = 75 patients). P was less
than 0.0001. Vitamin D2 long-term treatment was found to be helpful in
the prevention of osteonecrosis.
Ultrastructural exponents nephron damage in acute poisoning with
ethylene glycol/APEG. L. Cieciura, Z. Kidawa, S. Orkisz, and K.
Trznadel. Department of Histology and Clinic of Internal Diseases,
Military Medical Academy, Lód, Poland. Renal biopsy material from
five patients acutely poisoned with ethylene glycol in doses of 100 to
600 ml of 50% solution was examined. Renal biopsy was performed only
once in each patient after 5, 10, 16, and 22 days following poisoning,
respectively. Investigations by TEM revealed extensive crystal depos-
its in glomerular interloop spaces, leading to podocyte compression. In
part of the tubules crystals were found independent of time following
poisoning. No morphological evidence of reabsorption was found in the
tubules tightly filled with crystals, while tubules with empty lumen had
signs of compensation in the form of enhanced reabsorption. It was
manifested by numerous endoplasmatic vacuoles, distension of micro-
villous interspaces, parabasal invagination, and intercellular spaces. In
the early period of the poisoning, signs of epithelial damage with
abundant desquamation predominated, while in the late period signs of
epithelial regeneration prevailed. The results obtained give a new
insight into the pathogenesis of anuria in APEG, while the presence of
crystal deposits within the tubular lumen as long as 22 days after
poisoning must have its therapeutic implications.
The predictive value of hippuran uptake in acute renal failure. G. J.
Abels-Fransen, H. Y. Oei, H. A. Koomans, and E. J. Dorhout Mees.
Departments of Nuclear Medicine and Nephrology, University Hospi-
tal, Utrecht, The Netherlands. It was described that a good visualiza-
tion of the kidneys during a '311-orthoiodohippurate (°'I-OIH) study in
patients with acute renal failure predicted the recovery of renal func-
tion. However, visual interpretation of uptake on a scintigram seemed
inaccurate. We measured the uptake of '311-OIH in 30 patients with an
acute deterioration of renal function. The applied method was similar to
the previously described measurements of the hippuran uptake capacity
(HUC) in renal transplant patients. The HUC2 is the ratio between the
activity accumulated in the kidneys in the first 2 mm, divided by the
injected dose measured using the camera during standardized renogra-
phy. In the 30 patients we examined, 13 patients had (biopsy proven) an
acute glomerular disease (AGD) and 17 patients an acute tubular necrosis
(ATN) (diagnosed on clinical signs). During the deterioration of renal
function the HUC2 range was 1.3 to 3.0 (mean = 2.3, SD = 0.6)
in the AGD patients and 1.9 to 8.7 (mean = 4.5. SD = 1.7) in the ATN
patients. In only two patients of the ATN patients the HUC2 was below
3. In the AGD group renal function did not improve (N = 6) or
recovered partially (N = 7). Their ultimate serum creatinine was
elevated (range, 240 to 700 smoles/liter). All ATN patients made a
practically complete recovery. The serum creatinine of these patients
decreased to between 70 and 200 moles/liter. There is a good correla-
tion between the HUC2, measured during the acute phase, and the
serum creatinine measured after ultimate restoration of renal function.
These data strongly suggest that HUC2 can be very helpful in the
diagnosis and prediction of the outcome in acute renal failure.
Drug-induced granulomatous interstitial nephritis. P. Vanhille, D.
Kleinknecht, L. Morel-Maroger, A. Kanfer, V. Lemaitre, J. P. Mery,
P. Callard, M. Dracon, and J. Laederich. Services de Néphrologie,
Valenciennes, Montreuil, and Hôpital Bichat, Paris, France. The
discovery of noncaseating granulomas (G) with epithelioid cells on renal
biopsy specimens may be a clue to the diagnosis of acute interstitial
nephritis (AIN) due to drug hypersensitivity. Among 22 patients with
drug-induced AIN, interstitialG were found in eight patients (36%). The
drugs were cotrimoxazole (two patients), penicillin, hydrochlorothia-
zide plus triamterene, glafenin, floctafenin, noraminopyrine and parace-
tamol. Acute renal failure (ARF) was oliguric in three patients and
appeared within Ito 20 days after the beginning of therapy. Fever, skin
rash, arthralgias, and/or macroscopic hematuria were present in only
three patients, without marked blood eosinophilia. A rise in serum IgE
level was found in three of six patients, and circulating antibodies to the
drug in one patient. G within the renal interstitium were abundant in six
patients, and focal in two patients; focal or diffuse interstitial infiltrates
composed of lymphocytes, plasma cells with (four patients) or without
(four patients) eosinophils were associated features. All patients sur-
vived, but permanent renal damage occurred in three patients, despite
steroid therapy in one patient. In conclusion. (I) the diagnosis of drug-
induced AIN should be considered in any case of ARF of unknown
origin, even in the absence of symptoms suggesting a hypersensitivity
reaction; (2) the finding of G with epithelioid cells on renal biopsy is an
important diagnostic feature, especially when the interstitial infiltrates
do not contain eosinophils; (3) significant residual renal impairment
may be observed, and justifies prompt and definitive withdrawal of the
offending drug and of the related ones; the benefit of early steroid
therapy needs further assessment.
The effect of preventive administration of verapamil on acute ischemic
renal failure (AIRF) in dogs. M. Papadimitriou, E. Alexopoulos, V.
Vargemezis, G. Sakellariou, I. Kosmidou, and P. Metaxas. The effect
of verapamil, a calcium channel blocker, on the prevention of AIRF
was studied. In IS healthy mongrel dogs the kidneys were exposed
bilaterally and mannitol osmotic diuresis was instituted. Then, the renal
pedicle was clamped on one side (control kidneys) and 0.5 mg/kg of
body weight of verapamil was given intravenously. Ten minutes later
the renal pedicle of the other side was clamped (verapamil group). At
the end of a 60-mm ischemic period, blood flow was re-established and
renal function was studied for 2 hr after revascularization. The mean
time of initiation of diuresis was 7.2 (±2.5) mm in the verapamil group
and 20.3 (±3.6) mm in the control group (P < 0.001). In addition,
creatinine clearance was higher in the verapamil group (17.6 + 3.0 ml/
mm) compared with the control group (8.9 1.7 mI/mm) (P < 0.001). At
the end of the experiment the mean FENa reached 38.96% (±7.8) in the
control group, while it was 20.27% (±2.9) in the verapamil group (P <
0.01), and the mean LDH urinary excretion was 49.30 IU (± 17.2) in the
control group and 5.77 lU (±3.4) in the verapamil group (P < 0.05).
CNa, CK, Com, and Cure, were found significantly higher during the 2-
hr period of study after revascularization. In conclusion, it seems that
60-mm AIRF is significantly ameliorated by the preventive administra-
tion of verapamil which potentiates the protective effect of mannitol.
Studies on the glomerular filtration barrier and on the urinary excre-
tion of basement membrane (BM) glycoproteins during the accelerated
model of nephrotoxic serum nephritis (ANTS). J. C. Davin, J. M.
Foidart, C. H. Dubois, M. Davies, C. Dechenne, and P. Mahieu. State
University of Liege, Liege, Belgium, and Deparl,nent of Renal Medi-
cine, K.R.U.F., Card jff Wales. An ANTS has been induced in rats to:
(1) determine by histochemical and indirect immunofluorescence meth-
ods whether the anionic charges of the glomerular BM are altered
during the course of this disease; (2) evaluate whether these eventual
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alterations and the proteinuria might be correlated with the urinary
excretion of anionic BM glycoproteins or of neutral proteinases,
respectively measured using a RIA and radiolabelled substrates. The
following were noted between days 3 and 5 of ANTS: (I) a focal
reduction of colloidal iron staining only in glomerular areas infiltrated
by macrophages; (2) an increased urinary excretion of laminin and of
neutral proteinase activity; (3) a maximum level of proteinuria; (4) no
major changes in the pattern and intensity of staining of different
collagenous and noncollagenous glycoproteins; (5) a direct significant
correlation between the proteinuria and the laminin urinary excretion,
and between the latter and the urinary neutral proteinase activity. The
data suggest that one of the mechanisms of proteinuria in ANTS might
be a loss of anionic glycoproteins hydrolyzed by neutral proteinases
secreted by glomerular macrophages.
Cortical infarction in rabbits with serum sickness following cyclosporin
A therapy. G. H. Neild, K. Ivory, and D. G. Williams. Renal Unit,
Guy's Hospital, London, United Kingdom. Rabbits given acute serum
sickness (ASS) and treated with Cyclosporin A (Cy A) developed a new
renal lesion characterized by glomerular capillary thrombosis and
infarction. Electron microscopic examination showed that these lesions
were associated with severe endothelial injury and platelet-fibrin-
leucocyte thrombi. NZW rabbits received a single intravenous injection
of bovine serum albumin 250 mg/kg on day 0 and were given Cy A
therapy as follows: (1) 15 mg/kg/day from day —2 to +8, N = 5. (2) 25
mg/kg/day from day —2 to +3, N = 6. (3) 25 mg/kg/day from day 0 to
+5, N = 5. Signs of renal injury (hematuria, transient proteinuria,
glycosuria, and oliguria) occurred during the rapid phase of antigen
elimination when immune complexes were being formed. Eleven of the
16 rabbits developed glomerular capillary thrombi and 7 of the 11 also
had glomerular and tubular infarction. These changes were more severe
in the groups given 25 mg/kg. These lesions were not seen in untreated
rabbits with ASS, nor in normal rabbits given equivalent doses of Cy A
alone. A similar renal lesion has been reported in patients receiving Cy
A following bone marrow transplantation. Since we have shown in
other experiments that Cy A may impair prostacyclin synthesis by
vascular tissue, we suggest that when endothelial injury occurs in the
presence of Cy A a lack of prostacyclin can cause unchecked platelet
aggregation, capillary thrombosis, and necrosis.
Clinical course of renal insufficiency in lupus nephritis. R. S. Swenson,
D. A. Hall, and N. S. Coplon. Stanford University School of Medicine,
Stanford, California. We recently reported a favorable long-term
prognosis for survival and excellent rehabilitation in patients with lupus
nephritis who received long-term hemodialysis. Remission from renal
failure and discontinuation of hemodialysis were not unusual (8 of 28
patients) despite reduction or elimination in immunosuppressive drugs.
We examined the rate of change in serum creatinine (SC) to determine
whether a model could predict progression of renal failure to ESRD in
lupus nephritis. For 30 patients, dating from first observed elevated SC,
data were plotted as SC, I/SC and log SC versus time. Correlation
coefficients for the three models were, respectively, 0.91 0.07 (mean
so), 0.93 0.07, and 0.94 0.05. Correlation coefficients for log SC
were significantly better than for SC by paired t-test (P < 0.05). To
compare patients with a rapid versus a slow progression of renal failure,
patients were categorized by SC doubling times of less, or more, than 3
months. Twelve patients had SC doubling times of 25 16 days (mean
so), and 18 had doubling times of II 7 months. No one model was
superior to the others in analyzing the data from rapidly versus slowly
progressive renal insufficiency. Five of the eight patients with spontane-
ous remissions in renal failure had SC doubling times less than 3
months. Furthermore, patients experiencing partial remissions who
stayed off long-term hemodialysis tended to have shorter SC doubling
times. In summary, two of three mathematical models (1/SC and log
SC) accurately predicted the onset of ESRD. A high incidence of
spontaneous remissions was seen in patients with SC doubling times of
less than 3 months.
Ultrasonic findings in analegesic nephropathy. M. Weber, G. Braun,
and H. Kohier (introduced by D. Hoffler). I und II Medizinische Klinik
und Poliklinik, University of Mainz, Mainz, West Germany. Analgesic
nephropathy represents a common cause of renal insufficiency. An
increased risk for the development of uroepithelial carcinoma in pa-
tients with analgesic abuse is well established. Diagnosis is complicated
because analgesic abuse is often denied. Pathological hallmark is the
renal papillary necrosis which shows calcification in a high proportion
of the patients. In the present investigation we report characteristic
ultrasonic signs in patients with analgesic nephropathy. Twelve chronic
hemodialysis patients and 20 patients with renal insufficiency were
investigated, both groups with established diagnosis of analgesic
nephropathy due to prolonged excessive consumption of analgesics.
Calcified renal papillae surrounding the internal echo in a typical
garland pattern occurred in 70 to 80%. Patients with a history of renal
colic often showed an incomplete garland of papillary calcifications. In
several patients a combination of papillary calcifications with hydrone-
phrosis occurred as a consequence of ureteric obstruction by a de-
tached papillae. In severe renal insufficiency reduction of kidney size,
shrunken cortex, and a similar echogenicity of cortex and internal echo
was seen. In a second group of patients with renal insufficiency of
unknown origin ultrasonic examination in nine other patients uncovered
the typical ultrasonic finding of analgesic nephropathy. Tentative
diagnosis was confirmed by a hitherto unknown history of analgesic
abuse. Diseases showing similar ultrasonic signs like nephrocalcinosis
and diabetes mellitus have to be excluded. The diagnosis of analgesic
nephropathy is very important because of two reasons: (1) The long-
term prognosis of patients discovered before the onset of severe renal
insufficiency is good if analgesic abuse is discontinued. (2) Moreover,
analgesic abuse increases the risk for the development of uroepithelial
carcinoma. The search for previously unrecognized analgesic abuse by
ultrasonic examination is recommended even in dialysis patients with
unknown basic diagnosis of endstage renal insufficiency.
Incidence, diagnosis, and evolution of "non A-non B" hepatitis in
hemodialysis patients. R. Matesanz, J. L. Teruel, J. Glez, Sainz, R.
Bueno, R. Marcen, C. Quereda, andf. Ortuno. Centro Ramon y Cajal,
Madrid, Spain. Since 1977 to 1981, 154 patients were dialyzed in a HD
unit (70 at home). During this period 43 enzymatic elevations were
detected. HBs Ag (RIA) and serum alanin-transferases (SMAC-20)
were determined monthly. HBc Ab and HBs Ab (RIA) were tested
yearly. Whenever an enzymatic elevation was detected, after ruling out
drug toxicity, cardiac failure and bacterial infection, a virological
screening was done. (Epstein-Barr virus, CMV, 1gM-HA, HBs Ag,
HBc Ab and HBs Ab). According to these criteria, hepatitis was
classified as follows: virus A, I; virus B, I (in chronic carrier); CMV, 1:
EBV, 2, nor-etandrolone 4; and "non A-non B", 34 (79%). The
distribution of "non A-non B" hepatitis was uniform along these 4
years without epidemic outbreaks. Bilirubin was raised only in one
patient (4 mg/dl). There were no differences between hospital and home
HD patient incidences (10.7 vs. 10.6/100 patients-year). Blood transfu-
sion had been given to 16 patients (47%) during the previous 3 months,
and 64% when the hypothetical incubation period was extended to 8
months. However, at least in three home HD patients, blood transfu-
sions and contact through the machine could be totally excluded. Only
ten patients (29%) had a limited course, while 16 (47%) had a chronic
evolution (more than 6 months), and 8 (23%) showed relapsing enzy-
matic elevation. Non A-non B hepatitis are the most frequent kinds of
hepatitis in HD units whenever virus B prophylaxis is effective. Blood
transfusions seem to play an important role in the transmission.
Evolution is by no means benign as more than 70% became chronic or
showed a relapsing pattern.
Influence of aluminum hydroxide AL(OH)3 intake on hemoglobin (Hb)
levels and blood transfusions (BT). Requirements in hemodialysis (HD)
patients. J. Cannata, P. Ruiz Alegria, V. Cuesta, J. Herrera, and V.
Peral. Servicio de Nefrologia, Hospital General de Asturias, Oviedo,
Spain. Al(OH)3 has been used worldwide as a harmless phosphate
binder, however, there is increasing evidence of its absorption and risk
of bone marrow toxicity and of its action as a potential iron binder into
the gastrointestinal tract. The aim of this study was to evaluate the
likely influence of Al(OH)3 intake on the Hb levels and BT require-
ments in a group of 27 long-term HD patients followed-up during 24
months who were dialyzed with the same schedule over that time. The
follow-up was divided into two periods (P): P1, (months Ito /2) and P2,
(months 13 to 24). At the end of P1 the mean time on HD was 37.8 17
months. All patients received oral iron sulphate in a single fasting dose
(150 to 300 mg) over the 24 months. Intravenous iron was used
restrictively for short periods without stopping the oral iron in a few
patients who showed important iron deficiencies and did not raise the
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Hb level with oral supplements. During Fl they had Al(OH)3 (233 mg
tablets) three times each day at breakfast, lunch, and dinner. During P2
we reduced significantly the Al(OH)3 intake (P < 0.025) by stopping the
breakfast dose, keeping the iron sulphate away from the Al(OH)
influence. As the table shows the Hb levels increased after the Al(OH)3
reduction, the number of BT units required decreased significantly (P <
0.05) and the need for intravenous iron also decreased. Although the Al
(OH)3 intake reduction was significant, the mean serum phosphate
levels remained similar possibly because of a low phosphorous intake at
breakfast time in our patients.
Months
Hb
P1 P2
Al(OH)3
—12 —6 reduction +6 +12
(g/dl) 7.97 2.2 7.96 2.3 8.35 2.5 8.63 3.3 8.84 2.8
BT
P<0.05 I
ff3.19 BT U/patient/year—) f—1.5 BT U/patient/year—I
Intrave-
nous
iron
—15 glyear I I 9 gIyear—
Abbreviations: 1 l3T, 300 ml packed red cells or 500 ml whole blood;
U/patient, Unit/patient. (Values: mean SD)
Our results suggest that Al(OH)3 could interfere with erythropoiesis
either by its direct Al toxic effect on the bone marrow or by its likely
action as iron binder or by interfering with iron absorption through
duodenal pH elevations. On this basis we consider it advisable to avoid
the morning dose of Al(OH)3 which in many cases is not necessary and
could mean a multifactorial risk rather than a beneficial treatment.
Highly effective aluminum free intestinal phosphate binder. In vitro
and in vivo studies. H. Schneider, K. D. Kulbe, H. Weber, and E.
Streicher. Katharinenhospital and Fraunhofer-inst. Stuttgart, Federal
Republic of Germany. Aluminum accumulation and its sequelae in
chronic renal failure patients are mainly a consequence of aluminum
hydroxide medication. For the purpose of intestinal phosphate binding,
we developed a couple of substances consisting of natural polymers
charged with calcium (type I) and a combination of calcium and iron
(FE and Fe*) (type 2). These substances are atoxic and do not
cause constipation. They are produced in particles 1 to 2 mm in size,
containing very little sodium (20 mg/g) and potassium (7.8 mg/g). The
calcium content in types I and 2 is 140 to 160 mg/g; the iron content of
type 2 is 40 mg/g. The substances are resistant to acidotic pH. yet type 2
is capable of binding phosphate (16% of total binding capacity) under
acidotic pH condition via partial iron liberation. Coming to neutral and
alkalotic pH values (pH 7.5 to 8) in the presence of phosphate, the
beads swell allowing phosphate to be entrapped and kept in the
polymeric matrix. In in vitro experiments 0.4 g phosphate in Tris buffer
for different pH conditions was added to I g substance types I and 2 and
compared with the effect of I g Aludrox5. Type I is capable of binding
0.2 g phosphate (50%). type 2 binds 0.29 g (72.5%) in comparison to
Aludroxa, which binds 0.095 g (23.75%). Ten chronic renal failure
patients (nine on hemodialysis) showing inappropriate high serum
phosphate levels despite conventional aluminum hydroxide therapy
have been treated for 4 weeks to 3 months with type I substance in a
mean dosage of 3.6 glday. Side reactions have not been noticed.
constipation ceased, and serum phosphate levels dropped from 8.5
1.7 mg% to 5.5 1.1 mg% (35%).
Secondary hyperparathyroidism (HP'rH) in chronic hemodialysis
(CHD) patients: A clinicopathologic study. V. Al endes, V. Jorgetti, J.
Nemeth, C. Dubost, A. Lavergne, G. Cournot-Witmer, V. Lecharpen-
tier, and T. Drueke. Hôpital Necker-Enfants Malades, Lariboisière and
Fernand Widal, Paris, France. Severe secondary HPTH still occurs in
5 to 10% of HD patients and requires surgical correction. Fifty-eight
such patients were operated on and their 222 parathyroid (PT) glands
were analyzed. Mean individual PT gland weight was 689 62 SEM mg(range, 104 to 9775 mg) with a maximum total weight per patient
between 2 and 3 g. Schematically, four types of PT gland architecture
could be distinguished including diffuse hyperplasia alone; hyperplasia
was associated with early or marked nodule formation, or nodular
hyperplasia alone. Exclusively nodular or mixed hyperplasia was
associated with a significantly higher mean gland weight than the two
other histological forms (P < 0.001; P < 0.05) suggesting an alteration in
the expression of hyperplasia with time. Patients with chronic pyelone-
phritis had a higher mean PT gland weight than patients with chronic
glomerulonephritis (3308 498 mg, N = 18 vs. 1824 358. N = 18, P <
0.01). No correlation existed between PT gland weight and plasma Ca.
P, or alk. Ptases. However, a weak correlation was found between total
PT gland mass and plasma iPTH (C-terminal antibody. r = 0.41. P <
0.02). Interestingly, a negative correlation could be established between
plasma Al and total PT gland weight of less than 2000mg (r = 0.45, P <
0.05). In conclusion, in hyperparathyroid CHD patients initially diffuse
PT gland hyperplasia appeared to be followed by PT nodule formation
increasing with time. Plasma iPTH was positively related to total P1
gland weight. It was hypothesized that previous Al intoxication led to a
secondary decrease in PT gland mass.
Effect of secondary hyperparathyroidism (HPTH) on anemia of end-
stage renal failure: In vivo and in vitro studies. P. Grützmacher, H. W.
Radike, W. Fassbinder, K. M. Koch, and W. Schoeppe. Department of
Nephrology, University Hospital, Frankfurt, Federal Republic of Ger-
many. Severe HPTH with hypercalcemia and progressively increasing
serum PTH levels made parathyroidectomy (PTX) treatment necessary
in 28 of 160 RDT patients. In these patients renal anemia deteriorated
during the course of HPTH and improved significantly 6 to 12 months
following PTX (Hct 30.8 to 35.2; P <0.001). Serum erythropoietin (Ep)
concentrations were investigated pre- and post-PTX in six patients.
Since Ep did not change significantly (63 vs. 67 mU/mI), an increase in
Ep production could be excluded as the cause of the observed increase
in Hct. To investigate the effect of HPTH on erythropoiesis. in vitro cell
culture studies of murine fetal liver and human bone marrow cells were
performed in the presence of bovine 1—84 PTH. Whereas fetal mouse
liver cell colony forming unit-erythroid (CFU-E) .and human bone
marrow CFU-E formation was significantly elevated in the presence of
0.25 to 1.0 U/mI, a dose-related inhibition of CFU-E formation could be
observed in the presence of 2 to 8 U/mI. It is concluded that HPTH
participates in the development of the anemia of endstage renal failure
and PTX usually results in a significant increase in hemoglobin concen-
tration which is not mediated through increased Ep production. Eryth-
ropoiesis is directly inhibited by FTH.
Immunological monitoring of viral infections in renal transplant recipi-
ents. B. Brando, G. Civati, C. Grillo, G. Busnach, andL. Minetti. Renal
Unit, Niquarda-Ca'Granda Hospital, Milano, Ital. During a multiple-
assay immunological monitoring of 54 renal transplant recipients, ten
episodes of acute viral infection (7 CMV, 2 influenza, and I varicella-
zoster) were studied. T3, T4, T8, Tb. and 5/9 lymphocyte subsets were
determined by monocbonal antibodies; T-suppressor function was stud-
ied by two simultaneous assays, and anti-CMV lgG and 1gM antibodies
were measured by a micro-ELISA method. In all acute viral episodes,
the T8 subset increased and the T4/T8 ratio decreased (P < 0.01),
preceding the appearance of 1gM antibodies in all serum negative
patients. Tl0 and 5/9 subsets, and T-suppressor function increased
nonspecifically. In non-CMV patients the T4/T8 ratio returned to
normal in a few days. In CMV patients the T4/T8 ratio remained lower
than in controls for several months after the acute episode, despite the
reduction of the immunosuppressive regimen, in association with high
IgG titers and the disappearance of specific 1gM. Moreover, in 24
transplanted patients chronically positive for HBs Ag. the T4/T8 ratio
was persistently lower than in controls (P < 0.025). It is concluded that
monitoring T cell subsets may be a rapid and valuable tool in the
differential diagnosis between acute viral infections and rejection epi-
sodes. Moreover, it may provide earlier indirect evidence of acute
CMV infection in serum negative patients.
Hyperimmune immunoglobulin therapy for cytomegalovirus infections
in renal transplant patients. C. B. Brown, A. J. Nicholls, N. Edward, B.
Cuthbertson, P. L. Yap, and D. B. L. McClelland. Renal and Trans-
plant Unit, Royal Hallamshire Hospital, Sheffield; Renal Unit. A her-
deen; Scottish National Blood Tran.sfusion Service, Edinburgh, United
Kingdom. Nine renal transplant recipients with severe serologically
proven CMV infection have been treated by passive immunization: one
patient received high-titer anti-CMV plasma and eight patients were
given fractionated hyperimmune anti-CMV immunoglobulin. All pa-
tients treated had been pyrexial for at least 7 days before treatment and
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had typical clinical and laboratory features of CMV infection including
leucopenia. lymphocytosis, lung infiltrates, abnormal liver enzymes, or
deteriorating graft function. Three patients had been given antiviral
chemotherapy without effect. Seven of the nine patients treated showed
a complete and sustained response within 24 hr of antibody therapy. Of
the two patients who did not respond, one was the least clinically ill,
and the other had already developed a fungal superinfection. No side
effects were observed. It is concluded that passive immunotherapy is
highly promising for severe CMV infections in immunosuppressed
patients following renal transplantation. It may also have a role in
cardiac and more importantly, bone marrow transplantation.
Prognostic factors at renal retransplantation. B. Frisk, L. Smith, L.
Sandberg, and H. Brvnger. Department of Surgery land Blood Centre,
Sahigren's Hospital. Gothenhurg, Sweden. The frequency of retrans-
plantation in our center has been 29% during 1969 to 1980. Two hundred
and four second renal transplantations were performed. The study
comprised 183 as 21 patients had to be excluded as noninformative.
Patients with no lymphocytotoxic T-cell antibodies (47%) compared to
patients with antibodies (53%) had superior OS at I year (66% com-
pared to 43%, P < 0.01). The survival time of the first graft was
important to the survival time of the second graft. When the first graft
was lost in rejection within 3 months. 3 to 12 months, and after 12
months, the corresponding I year OS of the second graft was 34, 53, and
72%, respectively. The difference between the first and third groups
was statistically significant (P < 0.005). Blood transfusions to the
recipients before the first graft had no influence on survival of the
second graft. In conclusion, the presence of lymphocytotoxic T-cell
antibodies and short graft survival of the first kidney graft diminished
the chance for successful retransplantation significantly.
Different prednisolone pharmacokinetics in cushingoid and noncushin-
gold kidney transplant recipients. H. Bergrem, J. Jervell, and A. F.
Flatmark. Departments of Medicine and Surgery B, Rikshospitalet
University Hospital, Oslo, Norway. The pharmacokinetics and protein
binding of prednisolone have been studied in 16 cushingold and 46
noncushingoid long-term kidney transplant recipients in an attempt to
elucidate the possible connection between prednisolone effects and
pharmacokinetics. Prednisolone concentrations were measured by a
specific radioimmunoassay and protein binding by equilibrium dialysis
at 37°C. The cushingoid patients had a 9% higher peak concentration (P
< 0.05). an 11% longer elimination half-time (P < 0.03). a 20% larger
area-under-the-curve (AUC) of total prednisolone (P < 0.01), and a 15%
larger AUC of free prednisolone (P < 0.05) than the noncushingoid
patients. The prednisolone total body clearance was 17% (P < 0.02) and
13% (P < 0.05) lower in the cushingoid patients for total and free
prednisolone, respectively. The cushingoid patients had a significantly
(P < 0.02) lower creatine clearance, it is suggested that differences in
prednisolone pharmacokinetics influence the effects of prednisolone
and that reduced renal function may be an important contributing cause
of an increased glucocorticoid effect.
Transfusions induced anergy. Skin test as an index for pretransplant
transfusions. F. Anaya, R. Perez-GarcIa, E. Olivas, F. Vascona:, R.
Jofre, and F. Valderrdhano. Hospital Provincial, Madrid, Spain. We
have studied cellular immunity in vivo by delayed cutaneous hypersen-
sitivity (DCI-I) in 156 regular dialysis patients (RDP) and 51 healthy
controls, using multipuncture with seven antigens (MULTITEST). Of
RDP4fi.8% and of controls 5.8% were anergic (score < 5mm). Of RDP
32.7% and 76.4% of controls were responders (score> 10mm). Of RDP
20.5% and of controls 17.8% were intermediate (score 5 to 10mm). We
found a positive correlation between anergy in RDP and a young age,
the female sex, and ON as the cause of CRF and the number of previous
transfusions, but no correlation was found with cytotoxic antibodies.
HLA tissue typing or previous transplantations. Thirteen anergic RDP
were grafted and none of them lost the kidney by immunological causes.
but the only three responders we grafted lost the kidney by rejection. In
an attempt to study prospectively the effect of transfusions on DCH. 16
RDP that were responders received I U of concentrated blood. One
month later 12 converted to anergics (mean score lowered from 16.1 to
6.8 mm). The other four needed 2 or 3 U to become anergics. The
transfusions that induced anergy remained during a variable time (2 to 7
months), and new transfusions induced anergy again. A control group
of II responder RDP did not receive transfusions and remained
responders. In conclusion, anergy can be induced by transfusions and
probably their effect on graft survival could be mediated by depression
of cellular immunity. DCH measured by skin test is a good index for
transfusion requirements in RDP awaiting transplantation, avoiding an
excess of transfusions and its deleterous effects.
Interleukin-2 (IL-2) production after blood transfusions (BT) in pro-
spective kidney transplant recipients. J. C. Gluckman, D. Klatzmann, F.
Triebel, J. Rottembourg, C. Foucault, U. Assogba, and F. Metivier.
Unite d'Enseignement et de Recherche, Pitie-SalpétriCre, Paris,
France. it has been demonstrated that BTs performed in uremic
patients can induce the generation of mixed lymphocyte reaction
(MLR) suppressor cells, some of which may act through the production
of soluble suppressor factors (SF). Since lL-2 is a soluble mediator of
activated T lymphocytes (Ly), these data prompted investigation as to
whether suppression could be due to inhibition of lL-2 production and!
or IL-2 dependent proliferation. The effect of planned BTs on lL-2
production and MLR was investigated in previously nontransfused
patients. Supernates of PHA-activated pre- and post-BT Ly were
comparatively tested for IL-2 activity on an IL-2 dependent human T
cell line. Prior to BT, IL-2 production of the patients did not differ
significantly from that of normal donors, which indicates that the
classical depression of cellular immunity in uremia is not related to
deficit in IL-2 production. After BT, the occurrence of reduced lL-2
production, as compared to pre-BT levels, was less frequent than, but
significantly associated with (P = 0.03) a nonspecific decrease of MLR.
However, post-BT Ly could suppress the MLR but not the IL-2
production of autologous pre-BT Ly, when mixed in 3-cell experiments.
In addition, supernates containing SF did not affect the ability of lL-2 to
promote cell proliferation. Taken together, these results suggest that,
although IL-2 production correlates with post-BT decrease in MLR,
suppression of the production or activity of IL-2 is not a major
mechanism involved in this effect.
Differential diagnosis of cyclosporin (CyA) nephrotoxicity versus rejec-
tion by fine needle aspiration biopsy (FNAB). P. Havrv, E. von Wille-
brand, and J. Ahonen. Transplantation Laboratory. University of
Helsinki, Helsinki, Finland. To document the criteria for nephrotoxicity
versus rejection 12 transplants under CyA with signs of graft failure.
and five well functioning transplants were aspiration-biopsied as de-
scribed. These were analyzed for (I) the presence of inflammation, (2)
morphological changes in the graft parenchymal cells, and (3) the
presence of CyA in the renal tubular cells by indirect immunofluores-
cence and/or peroxidase. Three patients were recorded: (I) well func-
tioning transplants with a normal serum creatinine. no evidence of
inflammation but distinct parenchymal cell changes and massive depos-
its of CyA (that is. nephrotoxicity): (2) patients with elevated serum
creatinine, distinct inflammation in situ, modest tubular cell changes
and no CyA in the graft (that is, rejection); and (3) patients with
elevated serum creatinine, distinct inflammation in situ, distinct tubular
cell changes, and concomitant deposits of CyA (that is, nephrotoxicity
and rejection). CyA deposits in the graft had no relationship to drug
dose or concentration in serum. When the dose was reduced in (2), CyA
deposits rapidly disappeared and tubular cell changes normalized. The
inflammatory episodes in (3) were successfully treated with steroids.
Patients in (4). where the therapeutic margin was obviously too small,
were successfully transferred to azathioprine. We recommend the
FNAB for differential diagnosis of nephrotoxicity versus rejection in
renal transplantation in humans.
(± SD) N S-creat Inflammation
Tubular
cell ch
CyA deposit
in graft
0.8 0.3I 5 121 47 1.7 0.6 1.3 1.2
2 8 334 200 1.5 0.5 2.6 0.5 2.0 0.8
3 4 360 ISO 6.2 1.6 1.6 0.5 0.6 0.3
4 10 299 94 4.7 1.7 2.4 0.4 2.1 0.3
Improved graft prognosis by treatment of steroid resistant rejections
with ATG and plasmapheresis. W. Fassbinder. E. Scheuermann, P.
Bechstein. A. Fiirsch, and W. Schoeppe. Department qfNephrology,
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University Hospital, Frankfurt, Federal Republic of Germany. Conven-
tional therapy of acute rejection (AR) of renal graft is almost exclusively
based on increased steroid dosage; however, a considerable number of
grafts fails to improve and undergoes irreversible steroid resistant
rejection (SRR). Therefore, an alternative therapy is urgently needed.
We decided to treat SRR with ATG (antithymocyte globulin) or
plasmapheresis (PP), and to study the effects of this experimental
treatment prospectively. Since September 1980, 68 patients have been
grafted and allocated to the following antirejection regimen: AR was
initially treated with 2—3 x 1 g methylprednisolone injections. In SRR a
graft biopsy was obtained (3 to 4 days after the first pulse) and examined
histologically the same day. In case of persistent interstitial mononucle-
ar infiltrations ATG therapy (3 mg/kg/day for 10 days) was adminis-
tered; patients with predominant proliferative vasculopathy were treat-
ed with PP (6 x 5 liters plasma-exchange in 2 weeks). Sixteen patients
received ATG, 19 patients PP, and two patients both. Actuarial patient
and graft survival is given in the table (%).
Months post transplant
3 6 12 18 24
Patient survival 96.7 94.8 94.8 94.8 94.8
Graft survival 90.6 86.7 86.7 81.2 81.2
Graft survival was significantly (P < 0.01) longer than in historical
controls (N = 45), grafted 1979 and 1980 (1 year, 75.6%; 2 years,
68.7%). ATG or PP treatment did not increase mortality, and none of
the deceased patients received either form of treatment. Thus, ATG and
PP are valuable adjuncts in the treatment of SRR.
Critical role of oxalate restriction (OxR) in association with calcium
restriction (CaR) to decrease the probability of being a stone former
(PSF): Insufficient effect in idiopathic hypercalciuria (IH). P. Bataille, I.
Gregoire, G. Charransol, A. Pruna, J. F. de Fremoni, B. Coevoet, C.
Galy, and A. Fournier. Centre Hospitalo-Universitaire Amiens and
Institut de Hydrologie, Paris, France. Since simple dietary CaR in-
creases Ox excretion in all subgroups of calcium stone former (CaSF),
and increases the PSF index of Robertson in IH, the PSF was calculated
in three groups of idiopathic CaSF [normocalciuric (NC), dietary
hypercalciunc (DH), and IH, this latter group being defined by a Ca
excretion greater than 3 mg/kg on a CaRD of 400 mgldayl in four
conditions: on a free diet; on a Ca- and Ox-restricted diet (Ca, Ox)
during 4 days and after an oxalate load (200 g of spinach) while on a Ca
free (Ca) and on a CaRD (Ca).
PSF (absolute) zWSF wit
Ca
h Ox load
CaFree diet CaOx
Nca (N = 18) 0.56
DH (N = 7) 0.80
IH (N = 17) 0.77
Ø44a
0.48b
0.68
+ 0.11
+ 0.06
+ 0.02
+ 0.27w'
+ 0.36b
+ 0.24h
'P<0.02 bp<OOl
The table shows that combined Ca and Ox dietary restriction signifi-
cantly decreases PSF only in NCa and DH. In IH the decrease in PSF is
not significant because oxalate excretion significantly increases (33
39 mg/day) (P < 0.02) when dietary calcium is restricted despite
concomitant oxalate restriction. The oxalate load significantly increases
the PSF in all subgroups only when dietary calcium is restricted.
Conclusions are: (I) In all CaSF concomitant oxalate restriction is
critical to lessen the oxalate excretion increase induced by a CaR diet.
(2) In IH, however, this effect is not sufficient to significantly decrease
the PSF, suggesting that additional measures would be necessary.
Different effects of oral glycin and methionin on urinary lithogenic
substances. W. TschOpe, E. Ritz, H. Schmidt-Gayk, and L. Knebel.
Departments of Nephrology and Urology, University of Heidelberg,
Heidelberg, Federal Republic of Germany. Increasing evidence points
to an association between animal protein consumption and incidence of
nephrolithiasis. Our investigation examined the separate influences of
different amino acids, that is glycin, and methionin on the urinary
excretion of oxalate and calcium as major lithogenic ions. Nine male
individuals were examined during three metabolic periods (5 days
each): Control (CO), oral glycin (45 gld = 600 mmoles) (GLY), oral
methionin (6 g/d = 40 mmoles) (METH). Measurement of urinary
creatinine, urea, urate, citrate, P04, oxalate, Nat, K*, Ca**,
pH, cAMP; in plasma: Nat, K, Ca*+, albumin, creatinine, C1, P04.
Application of GLY resulted in increased excretion of oxalate (CO: 644
155 mo1es/24 hr; GLY: 797 194 moles/24 hr; P < 0.05), but not
of calcium (CO: 4.74 2.36mmoles/24 hr; GLY: 4.84 1.19 mmoles/24
hr, NS). In contrast, METH induced hypercalciuria (6.9 3.2 mmoles/
24 hr, P < 0.01) without increasing urinary cAMP (CO: 4.0 1.18
moles/day, METH: 4.3 1.04 moles/day, NS). METI-I was also
without effect on oxalate excretion (598 ISO imoles/24 hr). Urinary
citrate was higher under GLY and lower under METH. In neither
experimental condition GFR (Cr) was altered. In conclusion, the study
shows that protein ingestion increased both urinary calcium and oxalate
excretion by mechanisms mediated by separate amino acids. It ex-
plained some of the observed abnormalities in renal stone patients,
namely hypercalciuria, mild hyperoxaluria, and decreased urinary
citrate.
Dietary animal protein and urinary supersaturation in renal stone
disease. B. Fellstrom, B. G. Danielson, B. Karlstrom, H. Lithe/I, S.
Ljunghall, and B. Vessby. University Hospital, institute of internal
Medicine, Uppsala, Sweden. The potential effects of a dietary purine-
rich animal protein on factors important to renal stone formation were
studied in eight recurrent stone formers. The patients were housed in a
metabolic ward and fed on isoenergetic high and low protein diets
during 2 weeks on each diet. The diets contained 142 g protein per 2000
kcal (HPD) and 57 g protein per 2000 kcal (LPD), respectively. By the
end of each diet period measurements were made of electrolytes and
acids excreted. Calculations of supersaturation with respect to various
salts were made with a computer method. There was an increase in
urinary calcium and a decrease in urinary citrate on HPD. Furthermore,
the excretion of titratable acid and ammonium ions increased and
urinary pH decreased by 0.9 pH units on the high protein diet. Serum
urate did not change whereas urinary urate increased by 90%. The
calculated supersaturation of calcium oxalate did not change signifi-
cantly whereas there was a substantial increase in urinary supersatura-
tion of uric acid and ammonium urate. It is concluded that a high protein
diet may cause an increased risk of stone formation through a decrease
in urinary citrate and pH and an increased risk of forming uric acid and
ammonium urate crystals and stones.
Pyridoxine therapy in patients with renal calcium oxalate calculi. P.
Balcke, P. Schmidt, J. Zazgornik, H. Kopsa, andE. Minor. 1st Medical
Clinic, University of Vienna, Vienna, Austria. Pyridoxine administra-
tion is reported to diminish urinary oxalic and glycolic acid excretion in
patients with type I primary hyperoxaluria. Since urinary oxalic acid
concentration is also an important factor for the formation of calcium
oxalate calculi in patients with idiopathic renal stones, the effect of
pyridoxine in 12 patients suffering from recurrent calcium oxalate stone
incidents was studied. Determinations of urinary oxalic and glycolic
acid were done at the beginning and after 6 weeks of pyridoxine
administration (300 mg orally daily). Mean daily urinary oxalic acid
excretion decreased from 480.9 122.0 to 336.8 83.0mmoles within 6
weeks (normal range, 320.0 92.0 mmoles. The t test was used for
paired samples: t = 5, 46, P < 0.01. Mean daily glycolic acid fell from
28.3 51.8 to 153.3 26.3 mmoles (t = 3, 16, P < 0.05, normal value
210 80 mmoles). Our results show that the behavior of urinary oxalic
and glycolic acid excretion under pyridoxine therapy in these patients
was similar to that described in patients with type 1 primary hyper-
oxaluria. We assume that, by reducing calcium oxalate saturation,
the pyridoxine induced reduction of urinary oxalic acid excretion is
beneficial in preventing the formation of idiopathic calcium oxalate
calculi.
Placebo versus allopurinol for recurrent urinary calculi. V. Smith.
Division of Urology, Medical College of Virginia, Richmond, Virginia.
There is a subcategory of patients with calcium oxalate calculi that have
a mild serum uric acid elevation and uricosuria. A prospective blind
study was begun in 1970, and by 1975, 92 patients had been followed for
a minimum of 6 months and a maximum of 5 years when the code was
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broken. At that time, it was clearly demonstrated that there was a
placebo effect in the management of renal calculous disease and the
only event that appeared to separate the two groups was complete
cessation of calculous formation. In the experimental group, Atlopuri-
not was effective in 61% of the patients and this success could be
detected after 1 year of treatment. These patients have continued to be
followed over the ensuing 5 years. It has become clear that the
biochemical change that distinguishes the patients who will benefit from
the use of Allopurinol from those who will not is a urinary uric acid level
greater than 40 mg/dl in concentration. This long-term follow-up
continues to demonstrate that there is a placebo effect in all patients,
but that the drug is only effective in the group defined above.
Alternative treatment of cystinuria with alpha-mercaptopropionylgly-
cine (Thiola). T. Denneberg, J. 0. Jeppsson, and P. Stenberg. Divi-
sion of Nephrology, Department of Medicine, University Hospital,
Malmo, Sweden. Cystinuria is an inherited metabolic disease which is
mainly characterized by the excretion of abnormally high levels of the
amino acids cystine, arginine, lysine, and ornithine in urine. The most
promising form of therapy is changing cystine to a chemically more
soluble form, the mixed disulphide with D-penicillamine or alpha-
mercaptopropionylglycine (Thiola). The excretion of free cystine and
the mixed disulphide in urine has been quantified regularly by ion-
exchange chromatography. The excretion of free cystine in urine should
be less than 1200 moles/liter. Treatment was 0.5 to 2.0 g D-penicilla-
mine or 0.5 to 2.5 g Thiola given daily, the main part as a single dose at
night as well as supplements of vitamin B complex, B6, and zinc (during
penicillamine therapy). Clinical material consisted of 42 patients (22
women and 20 men) with an age range of 18 to72 years. Twenty-five of
the 42 patients were primarily treated with D-penicillamine (I to 15
years) and 16 of them (6 months to 4 years) with Thiola. All the patients
have a story of attacks of renal colic and had been treated surgically
several times before treatment with the drugs. We propose the treat-
ment of cystinuria with Thiola based on the quantitation of free cystine
and the mixed disulphide in urine. In the dose given Thiola has less side
effects than D-penicillamine on the bone marrow, kidney, liver, gastro-
intestinal tract, and skin. No chelating effect on urinary excretion of Cu
and Zn was observed during the Thiola treatment. By use of this
therapy, it is possible to inhibit the formation of cystine stones and
occasionally to dissolve cystine stones already formed.
Critical evaluation of various forms of therapy for idiopathic calcium
stone disease. M. Marangella, F. Linari. Ospedale Mauriziano Urn-
berto I di Torino, Italy. One hundred thirty-five idiopathic Ca stone-
formers were considered for this study. Stone history, main urine
constituent excretions, and levels of urine saturation with CaOx H,O
(B) and CaHPO4 2 H20 (Bbh) were recorded before entering the
treatment program and at regular intervals during treatment. After
patients were instructed to eat low calcium-oxalate diet and to increase
fluid intake, they were subdivided into three groups: A-35 patients to
whom no drug was added. B-35 patients, who were given allopurinol
300 mg/day. C-65 patients, who were given hydrochlorothiazide 50 mgI
day. Mean age (40 years), pre-treatment stone episodes and operations,
biochemical and physicochemical parameters, and mean treatment
follow-up (17.4 months) were similar in all groups. Stone episodes fell
from a pre-treatment mean value of 1.54/patient/year to a mean treat-
ment value of 0.57/patient/year (P < 0.001). One stone operation
occurred versus the expected 23. Twenty-four hour urine volume
increased, net Ca excretion and oxalate urine concentration decreased
during treatment. Estimations of and Bbh performed during
treatment follow-up showed the disappearance of peaks of urine
oversaturation. Clinical, biochemical, and physico-chemical findings,
which were not different in the three treatment groups, suggest that no
further benefits seem to be achievable when drugs are added to a careful
dietary management of calcium stone disease.
Hemodialysis performance in a single and a two-needle vascular access
system: A comparative study. R. Vanholder, N. Hoenich, M. Piron, and
S. Ringoir. Renal Division, University Hospital, Gent, Belgium. In
view of the renewed interest in single needle (SN) dialysis, the present
in vitro and in vivo studies were undertaken to compare small molecular
clearances in a pressure-pressure monitored SN system with the
corresponding data in a two-needle (TN) access system. In vitro small
molecular clearances were comparable for both systems: urea clearance
(CU) was 157 6 and 155 5 mI/mm and creatinine clearance (Car) 130
7 and 119 8 mI/mm for SN and TN, respectively (P = NS). In vivo
CU was 140 7 in SN and 143 7 in TN fistula dialysis, C, being 112
5 and 119 8 mI/mm (P = NS for all values). SN dialysis
performance with fistula (F) and central vein catheter (CV) was
compared in the same patients. In vivo CU was 157 6 for F and 144
5 for CV dialysis (P < 0.05), Cr being 124 5 and TN II 5 mI/mm,
respectively (P < 0.05). Average recirculation was 12 1% for F and 19
1% for CV (P < 0.05) and appeared to be mainly responsible for the
performance differences between the two access systems. Dialyzer
blood flows were 271 5 mI/mm for F and 277 5 mI/mm for CV (P =
NS). Performance data in a pressure-pressure monitored SN system are
comparable to the corresponding data in a TN system.
Myocardial perfusion and left ventricular performance during long (4
hr) and short (2 hr) hemodialysis in coronary heart disease (CHD). V.
Wizemann, W. Kramer, J. Thormann, M. Kindler, G. Schütterle, and
M. Schiepper. Zentrum Innere Medizin Giessen, Kerckhoff-Klinik Bad
Nauheim, Federal Republic of Germany. To assess the effect of short (2
hr) and long (4 hr) acetate hemodialysis on myocardial perfusion and
left ventricular (LV) function in CHD. seven patients (aged 36 to 56)
without a history of hypotension or unstable ang,na were studied during
both dialysis regimes. CHD was diagnosed by coronary angiography (3
of 7), positive exercise ECG, and thallium scintigraphy (7 of 7).
Simultaneous radionuclide ventriculography and thallium-20l perfusion
imaging was performed at rest and during exercise pre- and post-
dialysis. Volume removal was 2- or 4-hr in either dialysis. Heart rate.
blood pressure product, was unchanged (9.2 vs. 9.4 x l0). Ejection
fraction improved during dialysis (54.7 vs. 66.1%). but decreased at
peak exercise by 12% caused by a disproportionate increase in end-
systolic volume. Exercise duration (178 vs. 415 sec). max.ST-shift (2.78
vs. 1.8), angina score (2.57 vs. 142) as well as segmental wall motion
abnormalities improved postdialysis. Resting and exercise data did not
differ between 2- and 4-hr dialysis. In conclusion, (I) fluid overload
decreases myocardial perfusion and LV-function in CHD: (2) fluid
removal improves LV-performance and exercise tolerance at identical
work loads independent of treatment time (2 hr vs. 4 hr). (3) The degree
of mnterdiatytic weight gain and not the degree of fluid removal per time
seems to depress myocardial response.
A demonstration of neutrophil accumulation in the pulmonary vascula-
ture during hemodialysis. N. J. Dodd, M. P. Gordge, V. Parsons, and
M. J. Weston. Renal Unit, Dulwich Hospital, London, United King-
dom. In an investigation of neutropenia during hemodialysis (HD), we
employed '''Indium labelled autologous neutrophils to examine the
time course and distribution of their loss. Neutrophils, from two
patients on chronic HD, were separated by 'Ficoll-Hypaque' density.
gradient centrifugation. They wereIabelled with 250 Ci ''Indium
oxine and reinjected I hr prior to HD. Continuous surface counting was
carried out during HD over the right lung upper zone, spleen, and
dialyzer. Blood samples were taken at intervals for radioactivity and
neutrophil count. We found a marked increase in activity over the lung
up to 50% above predialysis counts, reaching a peak IS mm after
commencing HD. There was a coincidental fall in arterial and dialyzer
radioactivity, and a fall in the neutrophil count maximal also at IS mm.
Spleen counts, however, were stable and high, reflecting predialysis
sequestration of labelled neutrophils. After I hr lung activity had
returned to baseline consistent with reflux of labelled neutrophils into
the circulation, but, although arterial blood activity rose, it did not
return to predialysis values. In contrast, peripheral blood neutrophil
count returned to pre HD value suggesting an influx of previously
noncirculating neutrophils. Throughout the rest of dialysis. there was a
progressive increase in dialyzer radioactivity, as lung and blood activity
diminished, demonstrating neutrophil accumulation in the dialyzer. We
believe that this is the first direct demonstration of neutrophil accumu-
lation in the pulmonary vasculature during HD. Neutrophil accumula-
tion in the dialyzer may reduce dialyzer efficiency, and needs further
investigation.
Hemodialysis (HD), CAPD and cellular immunity. F. Collart, C.
Tielemans, L. Schandene, J. Wybran, and M. Dratwa (introduced by P.
Vereerstraeten). Bra gmann and Erasme University Hospitals, Bras-
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sels, Belgium. To verify the hypothesis that CAPD is able to restore a
normal cellular immunity, the latter was assessed in CAPD and HD
patients with regards to T lymphocyte subsets studied by monoclonal
antibodies identifying total (T3), helper (T4), suppressive cytotoxic (T8)
T cells, and to T cells suppressive function assessed using Con-A and
mixed lymphocyte culture tests.
Normal
CAPD
(N = 12) P HD(N = 36) P' b
t, month 35.6 3.8 40.4 6 NS
Age. year 65.7 2.8 50.3 2.5 <0.02
OKT3+, %68 2 69.6 2.6 NS 60 2 NS NS
OKT4+,%41 2 43.8 2.5 NS 42 2 NS NS
OKT8+,%27 8 21.1 1 <.001 19 I <0.001 NS
T4+/T8+ 1.6 I 2.18 2 <.02 2.5 2 <0.001 NS
Con-A, % 45.1 10 32.1 6.3 <.02 27.2 4.3 <0.005 NS
MLC, % 50.2 12.5 35.2 9.4 NS 20.5 3 <0.001 NS
vs. N controls. CAPD vs. HD. Means SEM
CAPD patients were older than HD patients, but their time on dialysis
(t) was the same. CAPD and HD patients showed a marked decrease in
OKT8+ cells with an increased OKT4+/OKT8+ ratio, and a much
poorer suppressive activity. There was no difference between HD and
CAPD patients with regards to OKT3+, OKT4+, OKT8+ cells nor to
Con-A and MLC tests. Between groups of CAPD and HD patients
matched for sex, age, and t there was also no difference, ruling out a
possible influence of age. In HD patients there was a negative correla-
tion between Con-A and t(r = —0.503; P < 0.01) while there was none
in CAPD patients. These findings suggest a worsening in T lymphocyte
function with time on HD but not on CAPD. They do not support the
idea that CAPD is more able than HD to restore a normal T lymphocyte
function in uremic patients.
Plasma concentrations and transperitoneal transport of native insulin
and C-peptide in patients on continuous ambulatory peritoneal dialysis.
T-E. Wideröe, L. C. Smeby, and 0. L. Myking. Department of
Nephrology and Institute of Biophysics, University of Trondheim,
Trondheim, The Hormone Laboratory, University of Bergen, School of
Medicine, Bergen, Norway. The insulin and C-peptide response to
glucose (50 g), given intraperitoneally or enterally and the elimination
rate of these compounds has been studied in five nondiabetic patients
on continuous ambulatory peritoneal dialysis (CAPD). Three hours
dwell time was needed to absorb 50 g glucose from the intraperitoneally
instilled 4.25% dialysate. Fasting C-peptide was three to ten times
normal values whereas fasting plasma insulin was within normal limits.
After intraperitoneal glucose load a more marked hyperglycemia (P <
0.05) and long lasting hyperinsulinemia (P < 0.05) was found than after
enteral glucose load. The relative change in plasma C-peptide was
slower and less pronounced in both experiments. Estimated total body
clearance (Ks) for insulin was 208.0 39.8 and for C-peptide 28.6 6.0
mlimin (P < 0.01). Dialysis clearance (Kd) for C-peptide was 4.35
0.40 and for insulin 2.75 0.64 mI/mm (P < 0.01). Markedly elevated
fasting C-peptide in plasma can only partly be explained by the absence
of normal kidney function, and suggests a continuously increased
production of C-peptide during CAPD. This was not reflected by the
fasting plasma insulin concentrations. C-peptide measurements in plas-
ma and in dialysate during CAPD could be helpful in evaluating the /3-
cell function in patients in need of exogenous insulin. Hyperglycemia
and increased /3-cell stimulation can be important in evaluation of the
feasibility of this form of treatment.
Use of urea kinetic model and hemofiltration (HF) to improve nitrogen
balance (Nb) in hemodialyzed (HD) children. M. Giani, M. Picca, A.
Saccaggi, L. Capitanio, R. Galato, A. Bettinelli, L. Ghio, A. Edefonti
(introduced by L. Minetti). Pediatric Dialysis Unit. University of Milan,
Milan, Italy. Nb is often negative in HD patients and has been reported
to affect growth in HD children. To improve Nb, ten pediatric patients
(11.2 2.7 years, 20.8 5.3 kg) in regular HD from 25.3 1.2 months
have been treated with HF for 10.2 3.5 months. HD was performed
according to the standard criteria recommended for pediatric age. HF
was prescribed using the urea kinetic model to ensure a pretreatment
BUN less than 130 mg/dl. Urea generation (Gu) and protein catabolic
rate (PCR) were computed by urea kinetics. Assessment of protein
(DPI) and caloric intake was performed in children on free diet by 10
days record every 2 months. The results are in the table:
CAL
kg/day
DPI
g/kg/day
Gu
mg/mm
PCR
g/kg/day
Nb
mg/kg/day
HD 58.13 2.04 4.03 2.10 —10.76
128.02
HF 62.3 2.2 3.2 1.64 47.63
P=NS P=NS P<0.05 P<0.05 P<0.05
All the patients undergoing HF had an increase of Nb. Three patients,
with negative Nb in HD, became positive. In conclusion HF treatment,
individualized using the urea kinetic model, seems to improve Nb in
pediatric patients.
Risks of orally administered Al (OH)3 in hemodialyzed patients and
results of withdrawal. F. Bournerias, N. Monnier, and R. J. Reveillaud.
Centre d'hemodialyse, Centre Hospitalier, St. Cloud, France. We
regularly dialyzed 23 patients (II females, 12 males: aged 28 to 73; mean
54 years) taking orally Al (OH)3 (3 to 12 g day) for 18 to 104
months (mean, 55 months). Al water and dialysate contents measured
every 6 months since 1979 were continuously 20 sg/liter and
aluminemia measured in all patients (jig/liter mean so): 1979, 73 29;
1980, 74 37; 1981, 74 45. Three of 23 developed Al related
morbidity in 1981: fracturing osteopathy three of three. Myoclonic
encephalopathy two of three; one of three died. Maximal aluminemias
were respectively 570 (died), 165, and 154 p.g/liter. Six additional
patients had EEG alterations. Oral intake of Al (OH)3 was completely
stopped in October 1981. We were able to follow 15 of the 23 (seven
females, eight males; mean age, 55 years). The results before (1981) and
14 months after (12-1982) Al (OH)3 withdrawal are:
1981 N=15 12-1982
Mean 50 Mean SD
Al, zg/liter 80 50 29 13 P < 0.01
P, mmoles/liter 1.8 0.31 2.1 0.37 P < 0.05
Ca, mmoles/liter 2.3 0.17 2.4 0.17 NS
Alkaline phos-
phatases lU/I 200 110 200 120 NS
(normal 200)
PTH ng/ml
(normal l.6) 4.5 1.9 3.9 1.3 NS
No significant alterations were seen on x-ray film of the skull (1981 vs.
12-1982). No worsening of osteodystrophy could be demonstrated
despite increased hyperphosphatemia. Aluminemia fell dramatically
and no other Al-related problems were observed. Orally administered
Al (OH)3 causes unacceptable morbidity in hemodialyzed patients for a
yet unproven benefit, and its prescription should be avoided.
Vitamin D metabolites in hypercalcemic and hypophosphatamic adults
after kidney transplantation. P. A. Lucas and R. C. Brown (introduced
by G. A. Coles). Welsh National School of Medicine, Cardiff, United
Kin gdom. Hypercalcemia and hypophosphatemia are frequently found
after renal transplantation. To study the relationship between these
states and vitamin D metabolism we measured l,25(OH)2D1.
24,25(OH)2D3, 25(OH)D3, and PTH in 19 subjects with transplants of
varying durations (mean, 33.7 months; range, I to 123 months) and in
six normal subjects. Of II hypercalcemic subjects, five were also
hypophosphatemic. Four normocalcemic subjects were hypophospha-
temic. Vitamin D metabolites were measured by radioimmunoassay
following lipid extraction and HPLC. PTH was measured by immunora-
diometric assay.
422 Abstracts
Post- Post-
transplant transplant
hyper- Normal normo-
calcemic subjects calcemic
1 ,25(OH)2D3
(Mean: pg/mI) 81.2 P < 0.05 53.0 NS 71.8
24,25(OH)2D1
(Mean: ng/ml) <0.14 P < 0.002 1.2 P < 0.002 <0.18
25(OH)D3
(Mean: ng/ml) >17.9 NS 24.1 NS >19.7
PTH
(Mean: nglml) 1.02 NS 0.6 NS 0.59
Re-expressing data in terms of creatinine clearance:
Ca
mi/mm normal(6) 57 to 77(8) 20 to 55(6)
1 ,25(OH)2D3
(Mean: pg/mI) 53.0 62.8 78.8
A significant elevation of plasma I ,25(OH)2D3 was found in hypercalce-
mic patients postrenal transplant. Levels of 24,25(OH)2D3 were signifi-
cantly lower than normal in both this group and normocalcemic patients
despite normal 25(OH)D3 levels. Impaired creatinine clearance was not
associated with lowered I,25(OH)2D3.
Vascular effects of parathormone (P'f H) after parathyroidectomy
(FIX) in eucalcemic spontaneously hypertensive rats (SHR) and in
normotensive Wistar Kyoto controls (WKR). J. Mann, M. Rambausek,
J. Bommer, and E. Ritz. Department of Internal Medicine, University
of Heidelberg, Heidelberg, Federal Republic of Germany. It has been
hypothesized that PTH plays a role in blood pressure (BP) regulation
independent of serum calcium levels. We therefore investigated the
vascular effects of PTH (bovine, 1—34) in SHR and WKR. Four groups
were investigated: (I) parathyroidectomized SHR (SHR-PTX); (2)
sham-operated SHR (SHR-SO); (3) WKR-PTX; (4) WKR-SO (N = 12/
group). PTX groups received high dietary calcium to normalize serum
calcium. PTH (1-500 U/kg) induced a log-dose dependent fall of mean
arterial pressure (MAP), measured in chronically instrumented, unre-
strained rats. The maximal effect was more marked in SHR(AMAP:
—41 3 and —48 2 mm Hg) than in WKR (iMAP: —29 4 and —32
3 mm Hg in PTX- and SO groups, respectively, P < 0.05 for both
groups). The differences between PTX- and SO-groups were not
significant. The increase in heart rate was comparable between groups
(121 12, 118 15, 122 9, 105 17, beats/mm in SHR-PTX, SHR-
SO, WKR-PTX, and WKR-SO, respectively). zHeart rate reached a
maximum at lower doses than MAP. Baseline MAP was lower in PTX-
than in SO-groups (P < 0.01); plasma volume and blood volume (Evans
blue dilution) were expanded in PTX-groups (P < 0.01), and lower in
SHR than in WKR (P < 0.05). In normotensive rat aortic strips (organ
bath), PTH caused a relaxation of 22 to 35% after stimulation with
105M norepinephrine. We conclude that (I) at rather high doses, PTH
induces a dose-dependent, acute vasodilation in vivo and in vitro which
is more marked in SHR than in WKR; and (2) in contrast, chronic
removal of PTH, with a concomitant high dietary calcium intake,
reduces BP and leads to expansion of the intravascular space.
Renal function in pregnant rats with 2-kidney Goldblatt hypertension.
A. Dal Canton, M. Sabbatini, C. Esposito, M. Altornonte, G. Romano,
F. Uccello, G. Conte, G. Fuiano, D. Russo, and V. E. Andreucci.
Department of Nephrology, Second Faculty of Medicine, University of
Naples, Italy. This study was performed in female Munich-Wistar rats
made steadily hypertensive (H) by placing a silver clip on the right renal
artery; rats with steadily normal blood pressure despite insertion of the
clip were used as normotensive controls (N). Three weeks after
clipping, the rats were mated and then housed in individual metabolic
cages from days 2 to 14 of pregnancy. During metabolic housing, Na
and water balance and tail-cuff systolic blood pressure (BP) were
monitored daily. At the end of balance studies, the rats were anesthe-
tized, and the left kidney was exposed for micropuncture. Micropunc-
ture measurements included single nephron GFR, glomerular and
peritubular capillary pressures, and flows and resistances in single
afferent and efferent arterioles. During pregnancy, BP averaged 165 mm
Hg in H rats and 124 mm Hg in N rats; in H rats, daily urinary excretion
of Na and water was significantly greater than in N rats (+50%). This
enhanced excretion was only in part counterbalanced by an increased
intake, so that cumulative Na and water retention was lower in H than
in N rats (—20%). In H rats, the only change in glomerular dynamics
was a moderate increase in glomerular blood flow. These results show
that hypertension in pregnancy causes a salt-losing tendency, that may
be secondary to incomplete renal autoregulation.
Erythrocyte sodium-potassium co-transport (Na/Kcotr) in hyperten-
sion. D. de Zeeuw, J. F. Jilderda, and T. Tepper. (introduced by G. K.
van der Hem). University Department of Medicine, Groningen, the
Netherlands. Controversy exists about the NalKcotr of blood cells as a
differentiating parameter between essential (EH) and secondary hyper-
tension (SH). We evaluated the NalKcotr in 28 normotensive controls
(NT) and 32 EH patients. The mean interassay variation was 5% (2 to
13%). Individual diurnal variation ranged from 6 to 22%, and day to day
variation from 4 to 39%. The mean NalKcotr in the NT group was:
sodium 386 164, potassium 437 166 moles/liter/hr. Interestingly,
these fluxes did not differ from those in the HT group: 388 185 and
442 241, respectively. The latter group was on placebo therapy and
used a 6 g sodium diet for at least 4 weeks. After 16 weeks of
antihypertensive therapy with either propranolol (P) or the converting
enzyme inhibitor enalapril (E), the fluxes were determined again in ten
patients of both groups. A variety of changes was observed, ranging
from a 32% rise to a 64% decrease (median, — 15%) in the P group and
100% and 124%, respectively, in the E group (—3%). We conclude that
in our observation the NaIKcotr of the erythrocyte is of no diagnostic
use for discriminating EH from SH. Beta-blockade and converting
enzyme inhibition neither have an unequivocal effect on these fluxes.
The great diurnal and day to day variation in the NalKcotr as well as the
variety of changes in the EH patients between the period without and
with antihypertensive medication is notable. This stresses the need for
caution with the interpretation of cross-sectional NalKcotr data of
hypertensive versus normotensive populations.
Effects of hemodialysis on active and inactive renin in nephric and
anephric patients. F. Vendemia, A. Morganti, A. Scalia, C. Sala, L.
Turolo, and G. D'Amico. Divisione di Nefrologia Ospedale S. Carlo,
Istituto di Clinica Medica IV, Universita di Milano and Centro di
Fisiologia Clinica e Ipertensione, Ospedale Maggiore, Milan, Italy.
Inactive renin is present in plasma of nephric and anephric subjects, but
the mechanisms which regulate its secretion are undefined. To evaluate
whether hemodialysis (HD), a known stimulus for active renin (AR),
affects also circulating inactive (cryoactivatable) renin (IR), we collect-
ed blood for measurement of AR and IR (ng/ml/hr) in four anephric (AP)
and in ten nephric (NP) patients before and after 4 hr of HD; for each
patient data were averaged from those obtained in three consecutive
HDs. Before HD AR was 0.2 0.1 in AP and 2.8 0.8 in NP; IR was
similar in AP and in seven NP (respectively, 2.9 1.0 and 2.5 0.7
while in the remaining three NP it was distinctly higher (34.2 2.9). In
AP and NP hemodialysis induced similar decrements in body weight
(2.2 0.1 and 2.0 0.1 kg), mean arterial pressure (5.2 3.0 and 9.9
3.9mmHg) and serum potassium (2.40.6and 2.0 1.0 mEq/liter). In
response to these stimuli AR was unchanged in AP whereas it rose, as
expected, by 2.2 0.7, that is, by 68% 10 (P < 0.01) in NP; in
contrast, IR increased only slightly both in AP (0.5 0.2 that is, 16%
7) and in all NP, regardless of the low or high values of IR before HD
(respectively, 0.6 0.2, that is, 23% 8, P <0.05, and 1.3 0.7, that
is, 4% 2). These data indicate that AR and IR change in the same
direction during dialysis; however, the magnitude of the response of IR
seems unaffected by the presence of the kidney and appreciably smaller
than that of AR in NP.
Plasma renin activity, blood uric acid, and plasma volume in pregnancy
induced hypertension (PIH). P. Fievet, L. Pleskof, I. Desailly, J. F. de
Fremont, B. Coevoet, and A. Fournier. Centre Hospitalo-Universi-
taire, Amiens, France. To get a better insight into the pathogenesis of
PIH, plasma renin activity (PRA), blood uric acid (UA), and plasma
volume (PV) were measured in 22 hypertensive pregnant women
(diastolic pressure > 90 mm Hg) after 20 weeks of pregnancy. PV was
measured by the Evans' blue dilution method and expressed in percent-
age of the normal theoretical value established according to body
Abstracts 423
surface and duration of pregnancy. PRA was measured by radio-
immunoassay of angiotensin I on blood samples taken from ambulant
women who had been in the supine position for 30 mm and who were
not taking drugs and were not on salt-restricted diets as ascertained by a
mean urinary sodium excretion of 140 mEq/day. Two groups of patients
were distinguished according to the response of their hypertension to
bed rest: the labile hypertensive group (LH = 6 patients) and the
permanent hypertensive group (PH = 16 patients) PRA was significant-
ly (P < .01) higher in the LH (11.5 0.7) than in the PH group (4.7 4
ng/mllhr) and in a control group of normotensive pregnant women (6.5
0.5). When all patients are considered, a significant negative correla-
tion (r =
—0.75, P < 0.001) is found between UA and PV. In the PH
group, there is a significant negative correlation (r = —0.62, P < 0.01)
between UA and PRA. In conclusion, (1) hyperuncemia of PIH may be
explained by hypovolemia; (2) PRA is lower in permanent PIH than in
labile PIH suggesting that these two entities have distinct pathogenesis,
since activation of renin secretion is not involved in the permanent form
of PIH, but involved in the labile form of PIH.
Severe side-effects of captopril in advanced chronic kidney insufficien-
cy. V. Beroniade. Hotel-Dieu de Montreal, Montreal, Canada. Out of
the last ten patients with advanced (Ce. < 30 mI/mm. three patients on
dialysis) chronic kidney insufficiency (CKI) treated with captopril that
we studied, four developed severe side-effects. Except in one patient,
captopnl dosage was limited to a maximum of 25 mg BID. Hyperkale-
mia was a rather constant finding. No other side effect was found in six
patients of whom two were on dialysis. Three patients had a severe
increase in CKI concomitant with an oligoanuria. One patient needed
two HD treatments; another, who was on peritoneal dialysis when the
treatment was started had a second exacerbation of her CKI 24 days
after the interruption of her CKI 24 days after the interruption of
dialysis and needed dialysis again. This patient, who simultaneously
developed an exfoliative erythrodermia, died from a straphylococcal
septicemia. The kidney involvement seemed to be an interstitial nephri-
tis. The fourth patient who was slightly thrombocytopenic before
treatment developed a severe pancytopenia. No precise hematological
disorder could be diagnosed before the treatment or at autopsy, 5
months later. All side effects were reversible. All patients except the
one who died of septicemia, recovered the C. fl 4 to 16 days. The HTA
control lasted 4 to 16 days after stopping the drug, suggesting that
plasma captopril remained in the therapeutic range for the whole
period. It is concluded that in patients with advanced CKI, captopril is
not a safe drug. The apparent protective effect of dialysis suggests that
even the lowest dosage could be inaccurate in those patients.
Restenosis of the renal artery after percutaneous transluminal angio-
plasty (PTA): An inevitable outcome? K. J. Kuiper, D. de Zeeuw, P. E.
deJong, K. H. Schuur, and G. K. van der Hem. University Department
ofMedicine, Groningen, the Netherlands. Thirty-three patients were
technically successfully treated for renal artery stenosis with PTA; 24
had atherosclerotic (AS) lesions; 9 had fibromuscular dysplasia (FMD).
Nineteen AS and seven FMD patients consented to follow-up angiogra-
phy after Ito 2 years. Re-stenosis was found in nine AS patients (group
I). The degree of stenosis pre-PTA was 54%, immediately after PTA
17% and on follow-up 64%; in the ten patients (group 2) without re-
stenosis 61%, 29% and 20%, respectively. PTA had an antihypertensive
effect directly after PTA in 44% and on follow-up in 22% of the patients
of group I. The beneficial effect on hypertension scored 60% and 70%
for patients of group 2. The characteristics of both groups before PTA
were compared: Neither age, duration of hypertension, renal blood
flow, systemic signs of AS, nor local parameters of stenosis (severity of
stenosis, length and distance from origin) showed a significant differ-
ence. Re-stenosis was found in one out of seven FMD patients. We
conclude that the chance of a re-stenosis is considerable in patients with
an AS lesion, as opposed to those with FMD. No prognostic factor was
found in the AS group to differentiate the re-stenosed group from the
group which did not develop re-stenosis. In some patients in the latter
group even an improvement of the local renal artery diameter was found
on follow-up angiography.
Renal involvement in systemic amyloidosis. M. Browning, R. Banks,
C. Tribe, P. Hollingworth, C. Kingswood, P. Harrison, and C. Mac-
Kenzie. Souihmead Hospital, Renal Unit, Bristol, United Kingdom.
One hundred and three patients with systemic amyloidosis have been
followed in a multidisciplinary amyloid clinic. An additional 21 patients
were examined at necropsy. Conditions underlying 76 patients with
systemic reactive (AA) amyloidosis included rheumatic diseases (72%)
and chronic infections (17%). Of 48 patients with immunoglobulin-
related (AL) amyloidosis 13 (27%) were associated with myelomatosis.
The mean survival times in patients followed from diagnosis to death
were 20.8 months for AA amyloidosis and 7.7 months for AL amyloid-
osis. Forty patients had renal biopsies, of whom 55% presented with the
nephrotic syndrome, 30% with persistent proteinuria, and 15% with
renal failure. Amyloid deposition was the sole renal pathology in 36
biopsy specimens. The mean percentage of glomerular volume replaced
by amyloid was estimated in 21 patients. Fourteen of 16 patients with
AA amyloidosis had less than 40% glomerular amyloid, while four of
five patients with AL amyloidosis had greater than 40% glomerular
deposition (P < 0.01). Glomerular amyloid correlated with urinary
protein excretion (P <0.05) in patients with AA amyloidosis. Necropsy
was performed in 30 patients with AL and 36 patients with AA
amyloidosis. Of these, renal involvement was found in 24(80%) AL and
all 36 AA disease and contributed to the deaths of 10 and 26 patients,
respectively. Renal vein thrombosis was present in two patients with
AA amyloidosis. Various drugs (penicillamine, chlorambucil, colchi-
cine, and dimethylsulphoxide) have been used without consistent
benefit. Five patients died while receiving acute peritoneal dialysis.
Three have started CAPD and all are doing well after 6 to 14 months.
Two patients treated with hemodialysis died after 4 months.
Role of plasma vasopressin in the impairment of water excretion in
nephrotic syndrome. M. Usberti, S. Federico, B. Cianciaruso, C.
Pecoraro, and V. E. Andreucci. Department of Nephrology, II Faculty
of Medicine, University of Naples, Naples, Italy. To verify if an
increased secretion of ADH may cause the water retention observed in
nephrotic syndrome (NS), 16 nephrotic patients and 13 control subjects
were studied in basal conditions and following a water load or an
isosmotic blood volume expansion (BV) by 20% albumin infusion. In
basal condition there were no differences in plasma ADH. urine output,
urinary osmolality (Uosm) and PRA between nephrotic patients and
control subjects, Posn,, PNa+, UNaV, and By, however, were signifi-
cantly lower in nephrotic patients. Following the water load, control
subjects reached a minimal Uom of 82 12 mOsm/kg at 60 mm and
completely excreted the ingested water in 150 mm; nephrotic patients
reached a minimal Uom of 160 11 mOsm/g at 120 mm, and the water
was eliminated completely in 240 mm. Plasma ADH decreased signifi-
cantly in the first hour following the water load only in control subjects.
A significant direct correlation was observed between plasma ADH and
P0 in controls but not in nephrotic patients. Plasma ADH was
inversely correlated with BV in nephrotic patients but not in control
subjects. In nephrotic patients the expansion of BV was effective in
reducing the plasma levels of ADH and in promoting a water diuresis.
Our results demonstrate a sustained volume mediated secretion of ADH
in the NS, which is responsible for the impairment in water excretion.
Interaction between macrophage system and IgA immune complexes in
IgA nephropathy. D. Roccatello, R. Coppo, B. Basolo, D. Cordonnier,
G. Picciotto, M. Sena, and G. Piccoli. Nephrology Units, S. Giovanni
Hospital, Turin, Italy, and CH Universitaire, Grenoble, France. A
primary role of IgA containing immune complexes (IgAIC) has been
suggested for Berger glomerulonephritis (BGN) and HenOch-Schonlein
nephritis (HSGN). To evaluate the possible interaction between IgA IC
and the macrophage system, six patients with BGN and three patients
with HSGN were studied by analyzing: (I) clearance of anti-D coated 51
Cr labelled red blood cells (RBC), (2) "in vitro" phagocytosis of anti-D
coated RBC by monocytes, (3) lgAlC (conglutinin assay), (4) C3d. The
half life of sensitized RBC was 28.6 10 mm in nine control subjects,
45.8 23 mm in six BGN and 48.5 19 mm in three HSGN. In two of
six patients with BGN and one of three with HSGN the clearance was
very delayed (> mean 2 s of controls). A strict correlation was
found between RBC clearance and "in vitro" phagocytosis (r = —0.75).
The two patients with BGN displaying a highly abnormal RBC clear-
ance had increased levels of IgAIC and of C3d also in the previous
follow-up. Moreover, they presented major signs of clinical activity,
and the most unfavorable course of the group. These data seem to
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suggest that if the macrophage system is defective in removing IgAIC
from the circulation, the renal load is increased, thus influencing the
course of the disease.
Delayed clearance of specific polymeric IgA immune complexes in
patients with IgA nephropathy. J. Sancho, J. Egido, F. Rivera, and L.
Hernando. Fundacion Jimenez Diaz, Madrid, Spain. High serum levels
of polymeric IgA are frequently found in patients with IgA nephrop-
athy, and several investigators have observed polymeric lgA at the
mesangial level. Considering the specific hepatobiliary transport of
circulating antigens, entering through the mucosal surfaces, by poly-
menc IgA, the possible existence of a defect in the clearance of this
immunoglobulin, in patients with IgA nephropathy was sought. Thus,
the presence of multimeric (polymeric and monomeric) IgA immune
complexes (IC), detected by Raji cell assay and by inhibition binding
assay, as well as the specific polymeric IgA-IC, determined by a
method recently described, was examined before and after the ingestion
of a large amount of proteins. A rise of multimeric IgA-IC occurred in
three out of seven control subjects with a peak at 2 to 4 hr after the
meal, and a subsequent return to normal. The amount of multimeric
IgA-IC present at fasting in four out of six patients diminished at 2 to 4
hr after food challenge reaching a new peak around 6 hr. In both control
subjects and patientS' the levels of IC containing antibodies against
dietary antigens (for example, ovalbumin) paralleled those of multi-
meric IgA-IC. The specific polymeric IgA-IC presented a maximal peak
with similar distribution to multimenc IgA-IC in control subjects, but
with a quicker disappearance from the circulation. By contrast poly-
meric IgA-IC remained elevated at 24 hr after food ingestion in most
patients. These results suggest that a defect in the hepatic clearance of
circulating polymeric IgA-IC exists in patients with IgA nephropathy.
Acute and chronic nephritides: Two different diseases? A. M. El
Nahas, R. Lechier, S. Zoob, and A. J. Rees. Royal Postgraduate
Medical School, Hammersmith Hospital, London, United Kingdom.
Chronic renal failure is often a relentless, irreversible process. Al-
though the mechanisms involved in the pathogenesis of acute, immune-
mediated nephritis are well defined, the progression of these nephritides
to chronicity remains poorly understood. The present experiment was
designed to determine the role of the antibody mediated immune
response in the progression of experimental nephrotoxic nephritis.
Acute nephrotoxic nephritis (NTN) was induced in rats by the injection
of rabbit nephrotoxic serum (NTS). One month later, nephritic kidneys
were transplanted into two groups of recipient rats: the first, pre-
immunized against rabbit globulin (RyG) and with high circulating
antibody levels, second, non-immunized, with no circulating antibodies
to RyG. The course of the nephritis in the recipients was compared for
each pair of kidneys. The progression to chronic renal failure was
unaffected by the humoral, antibody responses; proteinuria, renal
function, and histology were comparable for each pair, despite signifi-
cantly different (P < 0.025) circulating levels of autologous antibody.
The course of the nephritis was predictable by the pretransplantation
proteinuria (r:0.94) and serum creatinine (r:0.93). It becomes apparent,
in this model, that rat autologous antibodies, known to be of primary
importance in the induction of the nephritis, have no role in the
perpetuation of the injury and progression of the nephritis. It is likely
that further glomerular scarring depends solely on the extent of the
acute injury and the subsequent compensatory changes.
Chronic plasma exchange in SLE nephritis. W. F. Clark, D. C.
Cattran, J. W. Balfe, W. Williams, R. M. Lindsay, and A. L. Linton.
University of Western Ontario, London, Ontario, Canada; University
of Toronto, Toronto, Ontario, Canada; University of the West Indies,
Kingston, Jamaica. Thirty-two patients with systemic lupus erythemat-
osus and diffuse proliferative glomerulonephritis were enrolled in a
prospective study of chronic plasma exchange therapy. All patients met
a minimum of four of the ARA criteria for the diagnosis of SLE, and all
had at least one episode of ANA positivity, elevated DNA binding and
complement depression. Patients randomized into the pheresis group
(P) underwent 4-liter plasma exchange 1.3 to 4 weekly for a period of up
to 3 years. Both control (C) and P patients had biochemical assessments
of renal function, immunologic and clinical parameters measured 1.3 to
4 weekly throughout the study. With over 750 patient months of
observation, the P patients have undergone a 5% improvement and the
C patients have undergone a 25% deterioration in renal function. The P
patients have experienced a greater reduction in steroid and cytotoxic
therapy as well as a lesser frequency of episodes of elevated DNA and
Clq binding estimations. Chronic plasma exchange therapy is associat-
ed with significant preservation of renal function in patients with SLE
and diffuse proliferative glomerulonephritis.
Inhibitors of calcium oxalate crystallization in urine from stone formers
and normal subjects. D. S. Scurr, A. B. Latif, V. Sergeant, and W. G.
Robertson. Medical Research Council Mineral Metabolism Unit, The
General Infirmary, Leeds, United Kingdom. The study was designed to
measure the excretion and relative potency of various inhibitors of the
crystallization of calcium oxalate (CaOx) in the urine samples of stone-
formers and normal subjects. In terms of macromolecular inhibitors,
normal subjects excreted significantly more alcian blue precipitable
polyanions (ABPP) than stone-formers. Analysis of the various constit-
uents showed that this difference was attributable to their higher
excretions of glycosaminoglycans (GAGS), RNA, and Tamm-Horsfall
macroprotein (THM). In terms of small ionic inhibitors, there was
no difference, however, between either the magnesium (Mg), citrate
(Cit), or pyrophosphate (PP1) excretions of the two groups. The relative
potencies of the various inhibitors of calcium oxalate crystallization
were measured under "whole urine equivalent" conditions using both
continuous crystallization and batch crystallization systems. The order
of potency in terms of inhibition of agglomeration was found to be RNA
> GAGS > THM > PP, > Mg > Cit and in terms of crystal growth was
RNA > GAGS > PP, > Mg> Cit > THM. The order of ability of these
inhibitors to produce a high negative zeta potential on the surface of
CaOx crystals was RNA > GAGS > PP1 > Cit. This progression
correlates well with the observed effect of these inhibitors on crystal
agglomeration.
Study of inhibitor and nucleator activities in calcium stone formers. E.
Duranti, T. Grani, P. Imperiali, and M. Sasdelli. Divisione Nefrologia,
Arezzo, Italy. We studied 30 calcium stone formers to find the possible
correlation between the urinary excretion of citrates (Boehringer colon-
metric method), magnesium and formation product ratios of oxalate and
Brushite (FPRox, FPRbr — Pak's method). We have also studied
calcium, phosphorus, uric acid, and oxalate (colorimetnic method from
Hodgkinson and Williams) excretion comparing them with activity
product ratios of oxalate (APR0x), brushite (APRbr), and monosodium
urate (APRNaU, Pak's method). Statistical analysis was performed
using a computer program. We didn't find any significant correlation
between citrates, magnesium excretion, and FPRox-FPRbr. We notice
a significative correlation between calcium (P <0.001), phosphate (P <
0.05) excretion, and APRo-APRbr, while this correlation is not signifi-
cant for oxalate and uric acid. We conclude that citrates and magnesium
do not significantly modify the inhibitors urinary activity, so other
factors must be considered in cristallization inhibition; urinary oxalate
and uric acid do not seem to be important in nucleation and in variations
of urine saturation; on the contrary, calcium and phosphorus contribute
significantly to the increments of urine saturation.
Renal threshold phosphate concentration (TmPi/GFR) in patients with
idiopathic nephrolithiasis (IN) correlations with tubular functions, serum
parathyroid hormone (PTH) and 1,25(OH)2D. R. C. Pabico, B. A.
McKenna, and R. B. Freeman. University of Rochester Medical Cen-
ter, Rochester, New York. We have shown recently that proximal and
distal tubular functions are abnormal in IN: tubular maximum reabsorp-
tion of glucose (TmG/GFR) and secretion of PAH (TmPAH/GFR). U/S
osm after fluid deprivation and UHV following NH4CI load are
impaired. This report extends our study into the renal handling of
phosphate (Pi) and its relation to the tubular abnormalities. Seventeen
patients with IN were divided into two groups according to the level of
TmPi/GFR: Group I has less than 2.5 mg/dl and group 2, greater than or
equal to 2.5. GFR, effective renal plasma flow (ERPF), TmG/GFR,
TmPAH/GFR, U/S osm, plasma levels of PTH, andl,25(OH)2D were
measured:
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GroupN=
I
9
Group 2N=8 P
Serum Pi 2.5 0.13 3.5 0.11 <0.001
GFR, mI/mm 108 7 121 9 NS
ERPF, mi/mm 490 71 581 58 NS
TmG/GFR 1.93 0.3 1.82 0.3 NS
TmPAH/GFR 0.54 0.09 0.58 0.05 NS
U/S osm 2.3 0.2 2.l 0.3 NS
PTH, ng/ml 1.55 0.17 1.94 0.21 NS
l,25(OH)2D, pg/mI 32 3 36 7 NS
Four of group I and five of group 2 are hypercalciuric (UcaV> 300 mgI
day). The low TmPiIGFR in group I is not due to excess PTH, and the
hypophosphatemia has not led to elevated I ,25(OH)2D. All patients are
normocalcemic. Thus, the abnormal renal handling of Pi, present in
53% of our patients denotes another tubular functional abnormality in
patients with IN.
Relationship among Na intake, proximal tubular function and Ca
excretion (CaE) in normal subjects (N) and in idiopathic hypercalciuria
(IH). G. Colussi, M. E. De Ferrari, F. Maiberti, A. Marni, G. Pontor-
iero, G. Rombola, P. Cosci, M. Surian, L. Minetti. Renal Unit,
Niguarda Hospital, Milan, Italy. A proximal tubular dysfunction, with
reduced Na reabsorption (TnaR), has been suggested as a primary
defect in IH. Moreover, daily Ca excretion (UCaV) has been shown to
increase in IH following an increase in Na intake. Thus, we evaluated
the relationship between Na intake, TNaR (free water clearance
methodology) and UCaV in 15 N and 15 IH (UCaV 4 mg/kg/day on 1 g
Ca diet). During maximal water diuresis, Na excretion was correlated
with the previous day Na excretion (r = 0.8, P < 0.001) and was higher
in IH (173 78 Eq/min) than in N (60 59, P < 0.005); lH had also
higher distal Cl delivery (16.2 5.2%), higher CaE (0.12 0.09 mg/dl
GFR) and lower TmPO4/GFR (2.7 0.7 mg/dl GFR) than N (respec-
tively: 10.5 4.9, P < 0.01; 0.035 0.019, P < 0.01; 3.5 0.6, P <
0.05). Na excretion was correlated with distal Cl delivery (r = 0.72, P <
0.001), but not with CaE and TmPO4/GFR. Six N were studied both on
100 mEq and 200 mEq Na diets (with constant Ig Ca diet): distal Cl
delivery increased (from 9.5 3.5 to 17.3 7.5,P < 0.05) after high Na
diet, to values as high as in IH, without significant changes in UCaV
(from 151 65 to 174 86). In conclusion, reduced TNaR in IH seems
to be related to a high dietary Na intake. Since in N high Na intake is
associated with reduced proximal TNaR but not with hypercalciuria,
any pathogenetic link between reduced TNaR and hypercalciuria
remains to be clarified.
Calcium-loading-test and bone disease in patients with nephrolithiasis
B. Lindergârd, S. Colleen, W. Mdnsson, C. Rademark, and B. Rog-
land. Nephrological and Urological Departments, University Hospital,
Lund, Sweden. One hundred twenty-one patients, aged 20 to 60 years,
with a history of repeated nephrolithiasis, were studied consecutively.
Most of them were operated on at least once and had calcium-
containing stones and S-creatinine < 150 moles/liter. The calcium
loading-test according to Pak separated the patients into renal calciuric
(37%), absorptive calciuric (25%), and normal calciunc (38%). Neither
S-V1'H nor U-cAMP/creatinine differed in the groups. Five patients
with primary hyperparathyroidism had elevated U-cAMP after the
loading and had renal calciuna and lowered renal phosphate threshold
evaluated as Tmp/GFR. The 24-hr U-Ca/creatinine was increased in the
renal and absorptive group but not in the normal calciuric group
compared to normal control subjects. Bone mineral content, BMC,
measured with photon absorptiometry, was less in the renal calciuric
group compared to the other groups and the calcium/creatinine ratio
before loading correlated negatively with BMC. No difference between
the groups could be found for cortical bone volume index measured on
x-ray films of the hands. The Tmp/GFR in the whole material did not
differ from age-matched controls and there was no difference between
the groups. Nor did Tmp/GFR correlate with BMC or cortical bone
volume index. En conclusion it seems that patients with renal calciuria
in the calcium-loading-test have a negative calcium balance and that this
group should be treated with calcium-retaining drugs such as thiazides.
Management of infected stone disease with hydroxure: A five year
follow-up. V. Smith. Division of Urology, Medical College of Virginia,
Richmond, Virginia. An absence of formation of struvite stones has
been clearly linked to the enzyme urease produced by certain bacteria
found in urine. It has been shown that hydroxemic acids will block this
activity probably by competitive inhibition. One of these hydroxemic
acids, hydroxiurea, has been utilized in a morning dose of 500 mg.
Twenty-two patients have been on this drug 3 years or longer. Almost
all of the patients were able to acidify their morning urine, but not all
were able to maintain this acidity to the evening hours. Thus, a twice
daily dosage was begun and eight patients have been taking this drug 2
years or longer. There are no patients in this group who have had toxic
effects from the drug despite the theoretical ability that bone marrow
changes might occur over the long-term. It should, however, be
stressed that no patient who has a serum creatinine greater than 1.5 has
been allowed to enter the study. In most patients, Macrodantin 100 mg
at night has been used in conjunction with the drug and 78% have
persistently sterile urine. In only two patients has there been a decrease
in the size of the retained calculus, but in all, there has been no further
growth of stones.
Acetohydroxamate in struvite stones: In vivo study. A. Aroldi, G.
Graziani, C. Castelnovo, G. Colussi, and Ponticelli C. Nephrologic
Units, Policlinico, Niguarda, Milan, Italy. Prevention, stabilization and
dissolution of struvite stones have been reported in patients with urea-
splitting urine infections during acetohydroxamic acid (AHA) treat-
ment. In 13 patients with struvite stones and refractory urea-splitting
urine infections an association of intravenous antibiotic-pulse and oral
AHA (I g/day) was given for 5 days. This treatment achieved urine
sterilization in all patients. Then they were administered an oral
combination of AHA (0.5 to I g/day in two to four divided doses) and
antibacterial agent (pipemidic acid or trimethoprim) given at doses
adjusted on the basis of the serum creatinine. This course was given for
a mean period of 10.8 5.4 months. Within 2 months, urine pH (from
6.8 0.4 to 5.8 0.4, P < 0.01), urine bacterial count (col/ml) from
813830 13804 to 2511 630, P < 0.05) and urine NH4 (mg/dl) (from 80
31 to 36 15, P < 0.05) fell significantly, evaluated by Friedman's
test and Nemenyi's procedure. In the following period in only four of 13
patients urine remained sterile, but urine pH remained below 6.2 and
urine NH4 below 40 mg/dl. In all 13 patients, used as their own
historical control, the radiographic data showed an arrest of stone
growth during AHA therapy. Side effects were moderate and did not
necessitate discontinuation of therapy in any patient. In conclusion,
despite the persistence of urea-splitting urine infection in some patients,
the combination of AHA and antibacterial agents may prevent urine
alkalinization and supersaturation, so avoiding further struvite stone
growth.
Treatment of renal lithiasis associated with renal tubular acidosis
(RTA). C. J. Van Den Berg, T. M. Harrington, T. W. Bunch, and
A. M. Pierides. Mayo Clinic, Rochester, Minnesota. The clinical and
laboratory manifestations, roentgenographic findings, and treatment of
48 patients with RTA who were seen at the Mayo Clinic during the last
10 years were reviewed. Thirty-four (70%) had roentgenographic evi-
dence of renal lithiasis which was the presenting symptom in 23 (48%)
patients. In every instance, the calculi were multiple and with one
exception bilateral. While receiving therapy, 19 patients with renal
lithiasis were followed for longer than 1 year with sequential uroradio-
graphic studies. The mean duration of follow-up was 55 months, median
48 months, and range 13 to 120 months. Fifteen patients with renal
lithiasis were treated with an oral base alone (60 to 120 mEq daily).
Thirteen of these 15 patients had no evidence of new stone formation or
continued growth of existing stones during therapy. The two patients
with x-ray evidence of continued stone formation admitted to poor
compliance. Four patients received initial treatment with oral phospho-
rus (1.6 to 2.4 g phosphorus daily) as a neutral sodium and potassium
salt. Three of these four patients had roentgenographic evidence of
continued renal stone formation during 3, 5, and 8 years of phosphate
therapy. We conclude renal lithiasis is a frequent complication of RTA.
Adequate base replacement is effective therapy to stop continued stone
formation while oral phosphate therapy alone is often ineffective.
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Do thiazides prevent recurrent idiopathic renal calcium oxalate stones?
Results of a randomized, controlled clinical trial. H. Wolf, P. Brocks,
and I. Transbøl (introduced by F. JØrgensen). Hvidovre University
Hospital, Copenhagen, Denmark. In a double-blind controlled clinical
trial 80 patients with recurrent idiopathic calcium stone formation were
allocated either to treatment with bendroflumethiazide, 2.5 mg three
times daily, or placebo. In each group the rate of stone formation during
medication (average follow-up period, 3 years) was compared with the
rate of stone formation before medication (average control period, 3
years). In both groups a striking fall in the rate of stone formation to the
same level was found, from 0.40 to 0.09 number of stones per patient
year in the thiazide group and from 0.70 to 0.11 in the placebo group.
This indicates that thiazides in the present study did not alter the
spontaneous course of idiopathic renal calcium stone formation. It is,
therefore, doubtful whether life-long prophylaxis with thiazide is justi-
fied, at least in patients with moderate rates of stone formation as those
in this study.
Chemical renal medullectomy and experimental hypertension. G. J.
Russell, R. F. Bing, J. D. Swales, and H. Thurston (introduced by J.
Walls). Department of Medicine, University of Leicester, United King-
dom. Studies have indicated that the renal medulla has an antihyperten-
sive role in rats with experimental hypertension. Bromoethylamine
hydrobromide (200 mg/kg), an agent that selectively induces renal
medullary necrosis, was given to normal Wistar rats (N = 13) and the
subsequent effects on sodium balance, plasma renin concentration
(PRC), urinary prostaglandin E2 (PGE2), and blood pressure (BP)
compared with saline-injected controls. Bromoethylamine-injected rats
had an immediate, sustained increase in urine volume of low osmolality
together with an initial negative sodium balance which was restored to
normal by 7 days. PRC was normal in both medullectomized and
control rats and rose to similar levels on a low salt diet. High salt intake
suppressed PRC in the former group. Urinary POE2 was reduced in
medullectomized rats (148 54 vs. 466 74 ng/day, P < 0.01). This
suggests that the majority is derived from the renal medulla. High salt
intake stimulated urinary PGE2 in both control and experimental groups
although the difference was maintained. On a low sodium diet urinary
PGE2 was not different from normal diet. Direct arterial BP rose over 10
weeks in medullectomized rats and was then significantly different from
controls (136 3.3 vs. 119 3.7 mm Hg). This was not associated with
renal cortical damage, increased PRC, or sodium retention. The reduc-
tion in POE2 suggests damage to the renal medullary interstitial cells
which also produce other antihypertensive lipids. Chemical renal
medullectomy may provide an important model for unravelling the role
of the renal medulla in blood pressure control.
Epidemiology of hypertension in children. A. Papa, A. Dal Canton, A.
Capuano, G. Conte, F. DAnna, L. D'Avanzo, N. La Vecchia, and
V. E. Andreucci. Department of Nephrology, Second Faculty of Medi-
cine, University of Naples, Italy. Seven thousand and eight students,
aged 10 to 15 years, were examined in their schools by the authors.
Systolic and diastolic blood pressure (SBP and DBP), heart rate (HR),
and height and body weight (BW) were recorded. In the whole
population, both SBP and DBP rose linearly with age, the mean
increment per year being 2.5 and 1.1 mm Hg, respectively. When the
mean SD for corresponding age and sex-subgroup was taken as the
upper limit of "normal" blood pressure, 27.3% had "elevated" SBP
and/or DBP. Children with "elevated" blood pressure had a greater
BW (P < 0.0001) and ponderal index (P < 0.0001), and a higher HR (P
<0.0001) than "normal" children. A representative group of "normal"
children (N = 60) and children with "elevated" blood pressure (N = 72)
was randomly selected from the whole population and examined again
after I and 2 years. In 63% of children with "elevated" blood pressure
at the first control, SBP and/or DBP were "normal" in at least one of
the successive examinations. In the remaining 37%, SBP and DBP were
steadily greater than the mean + 2 so. In conclusion, this study defined
the mean values of SBP and DBP in a large children population. In this
population, excessive BW and higher HR were associated with greater
values of blood pressure. A blood pressure exceeding the mean + 2 SD
may be a correct criterion to select those children that are at risk for
future essential hypertension.
Influence of head-out water immersion (WI) on the renin-angiotensin-
aldosterone system (RAAS), vasopressin (ADH), and blood pressure (BP)
in women with late pregnancy toxemia. F. Kokot, A. Cekañski, and J.
Ulman. Departments of Nephrology and Gynecology and Obstetrics,
Silesian School of Medicine, Katowice, Poland. Head-out WI induces
significant systemic and renal hemodynamic changes in healthy sub-jects, which are accompanied by suppression of ADH and the RAAS.
The present study aimed to evaluate the importance of ADH and the
RAAS in the WI induced drop of BP in women with late pregnancy
toxemia. Forty-five women with EPH gestosis and 39 healthy pregnant
women were studied at the 39th to 42nd week of pregnancy. BP, plasma
renin activity (PRA), plasma aldosterone (PA) levels, and osmolaiity
were estimated before and 60 mm after head-out WI at bath t° 35 to
37°C. Both in toxemic and healthy pregnant women, WI was accompa-
nied by a fall in BP which was significantly more accentuated in EPH
gestosis. Simultaneously PRA, PA, and ADH fell to 31%, 60%, and
38%, respectively, of the basal values at 60 mm of WI. The correspond-
ing values obtained in toxemic women were 34%, 66%, and 45% and did
not differ significantly from healthy pregnant women. No significant
changes in plasma osmolality were noted. In conclusion, (I) WI induces
a significantly greater fall of BP in toxemic than in healthy pregnant
women. (2) Factors other than the RAAS and ADH seem to be involved
in the pathogenesis of hypertension in EPH gestosis.
Specific binding of '251-angiotensin H on human blood cells. J. F. E.
Mann, J. Sis, and E. Ritz. Department of Internal Medicine, University
of Heidelberg, Federal Republic of Germany. Several aspects of the
renin-angiotensin system are well characterized in humans. There is,
however, no method to study receptor-binding and -regulation of
angiotensin II (All) on human tissue. We therefore investigated binding
of '251-AIl on human blood cells. Cells were incubated with 0.02 mt
'251-AII and nonspecific binding was determined by adding 104M
nonlabelled All. No specific binding was found on red cells. On
mononuclear leucocytes (isolated by ficoll-isopaque density gradients)
specific binding was found, but binding did not reach an equilibrium
because of destruction of '251-AII. On platelets, specific binding was
one order of magnitude lower than on mononuclear leucocytes (per
cell). However, with I mp.s DFP and 5 mri EDTA binding reached a
stable plateau within 90 to 120 mm. Nonspecific binding amounted to
less than 15%. Using thin layer chromatography no degradation in the
incubation system could be detected. Binding was temperature- and
pH-dependent. With increasing concentrations of '251-AIl a saturation
was found. Scatchard analysis indicated two binding sites with high
(l0— mM) and low affinity. Specific binding was competitively antago-
nized by All > (des-asp')-AII > angiotensin I > multiple substituted
All-analogues. The specific binding was reduced by more than 80%
after mechanical destruction of the platelets and after hypoosmotic
shock. The investigations show that there are specific binding sites for
All on human platelets which may be useful to characterize the
regulation of these receptors in humans.
Prorenin and beta blockade in hypertension. F. McKenna and A. M.
Davison. Department of Renal Medicine. St. James's University Hos-
pital, Leeds, United Kingdom. Prorenin (inactive renin) can be mea-
sured in plasma following activation by several techniques. Prorenin
accounts for the majority of circulating renin yet its physiological role is
unknown; physiological stimuli to active renin have little effect on
prorenin. We have investigated active renin and prorenin in 44 patients
with essential (35) or renal hypertension (9) before and after selective
and nonselective beta blockade. The patients were entered to a random-
ized double blind trial of once daily nadolol or metoprolol. BP was
measured supine, erect, and with exercise. Sampling for renin was
taken at the end of a placebo run-in and after 18 weeks of treatment.
Active renin was measured by radioimmunoassay of angiotensin I,
generated at 37°C for I hr. buffer pH 5.7. Trypsin(l mg/mi) was used for
activation of prorenin prior to generation of angiotensin I as above.
Beta blockade reduced active renin; there was no correlation between
either pre-treatment renin or reduction of renin and change in blood
pressure. However, prorenin showed an inverse relationship with the
change in blood pressure; the increase in prorenin correlated with the
fall in systolic pressure (P = 0.05). Our data indicate that prorenin may
play a role in the response of hypertensive patients to beta blockade.
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Increase in serum potassium caused by beta-2 adrenergic blockade in
terminal renal failure: Absence of mediation by insulin or aldosterone. P.
Arrizabalaga, J. Montoliu, A. Martinez- Vea, L. Andreu, J. LOpez-
Pedret, and L. Revert. Nephrology Service, Hospital Clinic, University
of Barcelona, Spain. Beta adrenergic stimulation has been shown to
facilitate intracellular potassium (K) uptake, both in normal subjects
and uremic patients. Accordingly, beta blockade might be expected to
impair K tolerance in terminal renal failure. To test this hypothesis, we
gave propranolol, and then atenolol, to a group of 12 clinically stable
nondiabetic patients (mean age, 54 years) on chronic hemodialysis (HD)
and a constant diet containing approximately 50 mEq of K/day.
Propranolol. 60 to 80 mg/day for 10 days, induced a significant increase
in pre-HD serum K from 5.1 0.1 to 5.8 0.2 mEq/liter(P < 0.005).
The use in the same group of patients of atenolol (50 mg/day for 10 days)
did not produce a significant change in pre-HD serum K (5.5 0.2 to
5.2 0.2 mEq/liter). Both propranolol and atenolol decreased heart rate
(72 2 to 66 2 and 76 3 to 62 3 bpm, respectively, P < 0.02 for
both). Neither propranolol nor atenolol induced significant changes in
pre-HD plasma aldosterone, arterial pH, serum insulin, or blood
glucose. This shows that in HD patients, beta-2 adrenergic blockade by
propranolol is associated with a significant increase in serum K not
mediated by pH, aldosterone or insulin, and probably due to inhibition
of intracellular K uptake. Selective beta 1 adrenergic blockade by
atenolol at low doses does not change serum K, and therefore if
indicated in HD patients, cardioselective beta blockers might be
preferable to nonselective drugs.
Effects of enalapril (E) on blood pressure (BP) and renal hemodynamics
in essential hypertension. G. J. Navis, P. E. de Jong, and D. de Zeeuw
(introduced by G. K. van der Hem). University Department of Medi-
cine, Groningen, The Netherlands. The effect of E, a new non-SH-
containing converting enzyme inhibitor, was assessed in a double-blind
placebo-controlled study versus propranolol (P). Twenty-two patients
with mild to moderate essential hypertension were treated and titrated
with either E (5, 10, or 20 mg bid.) or P (40, 80, or 120 mg b.i.d.). In
both groups hydrochlorothiazide could be added after 12 weeks of
therapy. Titration was stopped when BP stabilized below 90 mm Hg. In
the P group 7 out of II patients achieved BP control. BP decreased from
154/102 4/I (mean SEM) on placebo to 132/87 3/2 mm Hg after 24
weeks of therapy (eight patients needed HCT). In the E group all
patients achieved BP control. BP decreased from 15 1/103 3/2 to 122/
82 6/2 mm Hg (six patients needed HCT). In the P group ERPF did
not change (423 24 mI/mm on placebo (mean SEM) versus 418 27
and 418 30 mI/mm after 4 and 12 weeks, respectively). In the E group
ERPF increased from 413 19 to 431 22 and 445 27 mI/mm (P <
0.05), respectively. GFR did not change in either group. No side effects
were observed. Enalapril appears to be an effective antihypertensive
agent with slightly beneficial effects on renal hemodynamics.
Percutaneous angioplasty for treatment of renovascular hypertension
(RH). D. Russo, A. Dal Canton, V. laccarino, A. Caputo, F. D'Anna,
C. Sforza, and V. E. Andreucci. Department of Nephrologv and 1st
Department of Radiology, Second Faculty of Medicine, University of
Naples, Italy. This study was performed in nine patients with RH, in
which blood pressure (BP) ranged from 150/100 to 250/140 mm Hg
despite antihypertensive medication. In seven patients, a renal-artery
fibrodysplasia was diagnosed by transfemoral aortography (in two the
lesions were bilateral); an arteriosclerotic stenosis was shown in the
other two patients. Plasma renin activity (PRA) in peripheral blood was
elevated in all but one patient with arteriosclerotic stenosis. In this
patient, and in the two who had bilateral stenoses, no renal venous PRA
gradient was found; this, however, was significant (that is, greater than
1.5) in all the other patients. In all patients, angioplasty was performed
by introducing into the stenosed renal artery a Gruntzig catheter via the
femoral artery, and inflating the balloon for a few seconds to a pressure
of 6 atm. The inflating maneuver was repeated until the stenosis
appeared dilated at angiographic control. After angioplasty, no adverse
reaction occurred; in five patients, BP was normalized and remained
normal until now (for I to 2 years) without any antihypertensive
medication. In three patients, normalization of BP was obtained using
lower doses of antihypertensive drugs tha prior to angioplasty. These
results show that percutaneous angioplasty is a simple, safe, and
effective therapy for RH.
Renal revascularization in 36 patients with total occlusion of the renal
artery. G. Dostal, H. D. Jakubowski, and F. W. Eigler (introduced by
N. Graben). Department of General Surgery, Universitat Klinikum
Essen, Essen, Federal Republic of Germany. From 1972 to 1982. 36
patients underwent revascularization of totally occluded renal arteries.
An additional renal artery stenosis contralaterally existed in ten pa-
tients, in seven of whom we performed a bilateral operative procedure.
All patients had severe hypertension, controlled insufficiently by medi-
cal treatment. Preservation of renal function was the main indication for
surgery in 16 patients. A revascularization of the occluded artery could
be performed in 33 patients; a nephrectomy had to be done primarily in
three patients. Hospital mortality was 14%; the causes of death were
cardial or cerebral complications. Three early nephrectomies had to be
performed because of thrombosis and one because of massive intrarenal
hemorrhage. Renal function improved in 5 of II patients with preoper-
ative azotemia and stabilized in 6. Hypertension was cured or improved
in 80% of all patients. Revascularization of a chronic occluded renal
artery has a high rate of success, but the significant postoperative
mortality in a group of high risk patients indicates the difficult problem
of correct selection of patients for operation.
Is renal glucosuria a benign condition? S. Dc Marchi, E. Cecchin, G.
Proto, D. Schinella, A. lengo, A. Basile, D. Villalata, G. F. Santini,
and F. Tesio. Department of Internal Medicine, Ospedale Codroipo;
Renal Unit and Department of Immunology. Ospedale Civile, Porden-
one, Italy. The occasional discovery of significant autoantibody titers
against thyroglobulmn and thyroid microsoma in a woman with renal
glucosuria (RG), prompted us to evaluate a group of families with RG
for both HLA typing and a variety of other immunological parameters.
We studied autoantibodies and HLA genotyping in five unrelated
affected families with a total of 24 patients and 39 healthy relatives.
Other inherited or acquired renal tubular dysfunctions were excluded.
Our data indicate that the gene responsible for RG segregates with the
HLA complex suggesting a close genetic linkage. In each family the
abnormal gene is contained between the HLA-A and C locus or just
outside the HLA-A locus. All affected members have significant
autoantibodies titers to nuclear antigens, native DNA, smooth muscle,
hepatic reticulin, thyroglobulin, thyroid microsoma, and renal tubular
brush border. On the other hand, unaffected members have no signifi-
cant autoantibodies titers. Our findings suggest that RG is a HLA
complex-linked disease with an abnormal autoantibodies production.
Further studies are needed to evaluate the risk of autoimmune diseases
in patients affected with RG.
Insulin resistance in uremia. An insulin receptor or an intracellular
defect? 0. Schmitz, C. Hasling, E. HjØllund, H. E. Hansen, V. P.
Petersen, and H. Beck-Nielsen. Medical Department C, Aarhus Kom-
munehospital, and Medical Department III, Aarhus Amtssygehus,
Aarhus C, Denmark. Although insulin resistance in uremia is very
widely prevalent, the mechanisms responsible for this defect are still
debated. The present study was performed to examine the possible
participation of an insulin receptor defect and of abnormalities in the
intracellular glucose metabolism and to evaluate the effect of dialysis.
Therefore, insulin binding capacity of monocytes was estimated and the
glucose metabolism corresponding to the glucose input in steady state
was registered during increasing levels of insulin concentration by an
artificial endocrine pancreas. In this preliminary study we have investi-
gated four patients twice, namely a mean of 6 2 days (± SEM) before
dialysis and again after a mean of 27 4 days on chronic dialysis.
Maximal glucose metabolism increased from 6.9 0.5 mg/kg/mm to
11.7 0.6 mg/kg/mm (P < 0.01) after commencement of dialysis
therapy. In addition the plasma insulin required to achieve half-maximal
stimulation of glucose metabolism decreased after dialysis (103 II
zU/ml vs. 77 6 jzU/ml; P < 0.05). In contradistinction no difference in
insulin binding to monocytes in the two situations occurred. In conclu-
sion, the results indicate that insulin resistance in uremia is primarily
due to a postbinding defect, that is, an impaired intracellular glucose
metabolism or an abnormal glucose transport system. Dialysis often
normalizes intracellular glucose processings.
Intraperitoneal insulin (IPI) regimens and diabetic nephropathy (DN).
R. L. Stephen, J. G. Maxwell, D. Kah/itz, S. C. Jacobsen, B. Hanover,
and F. Tyler (introduced by W. J. KoIff). University of Utah. Salt Lake
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City, Utah. Eleven patients suffering type I diabetes and DN, not
treated by peritoneal dialysis, were placed on long-term multiple daily
injection IPI regimens. Group I (N = 6) started with serum creatinine
(Cs) values of 1.3 to 2.8 mg/dl and creatinine clearances (Ccr) of 25 to 75
mi/mm and were followed for 5 to 24 (mean, 16.5) months. Group 2 (N
= 5) had more severe renal failure (Cs 4.5 to 6.8 mg!dl, CC < 20 ml!
mm). No patient in group 1 showed a significant decline in renal
function (measured by reciprocal serum creatinine and creatinine
clearances), rather, two patients improved significantly while four
remained stable. Proteinuria increased significantly in one patient,
decreased significantly in two patients, and was stable in the remaining
three patients. Glycosylated Hb (HbA1) levels were significantly low-
ered, with four patients demonstrating values consistently within nor-
mal range. All group 2 patients showed continuing decline in renal
function with consistently normal HbA1 values. Three have com-
menced dialysis, while two with functioning transplants (-5 months
each) continue with IPI and normal HbA1 levels. In summary, IPI
regimens offer a chance of stabilizing renal function in patients with DN
who still retain greater than or equal to 25% renal function. IPI regimens
will not arrest declining renal function in patients with less than or equal
to 20% residual renal function.
Long-term survival on CAPD. C. T. Flynn. Iowa Lutheran Hospital,
Des Moines, Iowa. To date we have trained 61 patients in CAPD; 29
patients are diabetic and 19 of those are blind. Most nondiabetic
patients had definite indications for CAPD. Diabetic patients used
intrapentoneal insulin exclusively; several patients with CAPD-induced
diabetes were likewise treated. Permanent silastic connecting tubes
were used. Self-care was achieved in 59 patients initially, including 18
blind persois. One blind and five others needed significant help later.
Hemodialysis was required at some time after CAPD for 25 patients,
but, excluding deaths, permanent drop out was l4% at 4.5 years.
Survival on CAPD at 4.5 years was: (I) blind diabetic patients 60%, (2)
nonblind diabetic patients 50%, and (3) nondiabetic patients 40%.
Peritonitis rates steadily fell. Current rates are: (I) blind diabetic
patients 1/96 weeks, (2) nonblind diabetic patients 1/54 weeks, and (3)
nondiabetic patients 1/40 weeks. Similar trends in CAPD-related prob-
lems and hospitalizations were found. Intraperitoneal insulin was found
safe and effective. Diabetic patients on intraperitoneal insulin had
significantly lower triglyceride levels than nondiabetic patients. Our
results suggest: (1) Highly motivated patients do best and survive
longest on CAPD, the blind being outstanding. (2) Ready access to
hemodialysis is necessary to support a successful CAPD program.
Progress in segmental neoprene-injected pancreas transplantation.
Advantages and disadvantages of using cyclosporine A. J. Traeger, J. M.
Dubernard, E. Bosi, A. Secchi, J. L. Touraine, S. El Yafi, A. Gelet, A.
E. Pontiroli, and U. Pozza. Hôpital Edouard Herriot, Lyon, France,
and University of Milan, Milan, Italy. Thirty-four segmental neoprene-
injected pancreatic allografts were performed in 32 insulin-dependent
diabetic patients (1.D.D.) from 1976 to January 1983. In II patients the
pancreas was transplanted alone, in 23 associated with kidney, simulta-
neously (20) or at different times (3). Donors were all heart-beating
cadavers selected for ABO compatibilities and unmatched for HLA
antigens. Immunosuppressive therapy consisted in the first series of
azathioprine plus ALG plus steroids, in the last series it included
Cyclosporin A (CyA), temporarily associated to ALG and/or steroids
according to different protocols. The best results were obtained in the
simultaneous pancreatico-renal series with a graft-functioning survival
rate of 47, 40, and 26% at 6, 12, and 24 months, respectively, while only
3 of 11 patients who had single pancreatic transplants survived more
than 3 months. The use of CyA further improved the pancreatic graft
survival of the double transplant group, attaining 54, 44, and 44% at 6,
12, and 21 months versus 38, 38, and 12.5, respectively, for the
conventionally treated group. When successful, pancreatic allografts
were able to reverse the metabolic abnormalities of diabetes, achieving
near physiological levels of glucose, lactate, BOH-butyrate, and gluca-
gon during the 24 hr. A better glucose tolerance and a more physiologi-
cal insulin release was achieved when CyA was used instead of
steroids. Some patients with circulating immunoglobulin abnormalities
and three patients with fatal infectious and lymphoproliferative syn-
dromes occurred in the CyA-treated group, perhaps because of a major
immunosuppression induced by the association CyA-ALG.
Renal and pancreatic transplantation in the treatment of diabetic renal
failure. J. Michael, P. McMaster, D. Ada, 0. M. Gibbv, and J. H.
Turney. Queen Elizabeth Hospital, Birmingham, United Kingdom.
Diabetic patients make up a smaller proportion of the renal failure
population receiving treatment in Britain than in some other European
countries and in North America. We report our recent experience.
Since January 1981, 20 diabetic patients in renal failure have been
accepted for treatment. Eight have undergone combined cadaveric
renal and segmental pancreatic transplantation with Cyclosporin A; one
received a renal graft alone and the remainder are on CAPD. Seven of
14 transplanted patients (mean age, 33) received CAPD and one
hemodialysis prior to transplantation. Two pancreatic grafts failed from
early thrombosis, one kidney failed from vascular rejection. One patient
died I month post-transplant with two functioning grafts. Five patients
experienced both grafts functioning at 2 weeks, 10, II, 16, and 20
months, respectively, and are not receiving insulin. Of the patients on
CAPD (mean age, 42) two died from myocardial infarction. Hemoglobin
A1 concentrations are lower in the group with pancreatic grafts (mean.
8.3%) than in the CAPD group (mean, 12%). With a flexible multidis-
ciplinary approach renal failure in diabetes can be managed successful-
ly. The results of combined renal and pancreatic transplantation contin-
ue to show promise. The possibility that combined organ grafting might
lead to the amelioration of microvascular complications in diabetic
patients remains.
